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CHAPTER I 
                                Review of the Literature 
 
1.1 Protein folding  
Proteins are the most abundant biological macromolecules within a cell and 
carry out vital functions. The sequence of amino acids in a protein defines its 
primary structure. However, the linear chain of amino acids only becomes a 
functional protein when it folds into its three-dimensional form. 
 
1.1.1 Protein sequence and protein structures 
 All proteins are polymers of amino acids (8). Each protein polymer – also 
known as a polypeptide – consists of a sequence of 20 different L-α-amino acids, 
also referred to as residues (9). To be able to perform their biological function(s), 
proteins fold into one or more specific spatial conformations, driven by a number 
of non-covalent interactions such as hydrogen bonding, ionic interactions, Van 
der Waals forces, and hydrophobic packing (10, 11). 
 Proteins have four structural levels. The primary structure refers to the 
amino acid sequence of the polypeptide chain, which is held together by covalent 
bonds (peptide bonds). The secondary structure refers to highly regular local 
sub-structures. Two main types of secondary structures are the α-helix and the 
β-sheet. These secondary structures have a regular geometry, being constrained 
to specific values of the dihedral angles φ and ψ on the Ramachandran plot. The 
tertiary structure refers to three-dimensional structure of a single protein 
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molecule. The α-helices and β-sheets are folded into a compact globular 
structure driven by the non-specific hydrophobic interactions and is stable only 
when the parts of a protein domain are locked into place by specific tertiary 
interactions, such as salt bridges, hydrogen bonds, and the tight packing of side 
chains. Quaternary structure is a larger assembly of several protein molecules 
(subunits). These quaternary protein subunit assemblies are stabilized by the 
same non-covalent interactions as the tertiary structure. 
 
1.1.2 Protein folding 
Protein folding occurs through an intermediate form, known as secondary 
structure. The most common secondary structure elements are the rod-like α-
helix and the plate-like β-pleated sheet. They are stabilized by non-covalent 
interactions. Then, in turn, these secondary structural elements further interact, 
fold, and coil to produce the tertiary structure that contains functional regions 
(domains). 
Although it is possible to deduce the primary structure of a protein from a 
gene sequence, the tertiary structure or the quaternary structure of a protein 
cannot be predicted just by its primary amino acid sequence. Meanwhile, inside 
the cell, the folding rate is significantly high, in a second time-scale (12). 
Therefore, to understand how a protein sequence folds into its functional 
structure inside of the cell becomes one of the most important tasks for 
biochemists.   
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One of most popular models for protein folding is the hydrophobic collapse 
model. This model proposes that, since the hydrophobic effect is the major 
driving force for protein folding, formation of a hydrophobic residue cluster that 
repels water must be the first step of folding. The polypeptide chain tends to 
collapse to a compact state. Then the rate-limiting steps in folding can be the 
reorganization of inter-residue interactions within a more-or-less disordered 
collapsed state (13). This process involves complex kinetics. Some molecules 
may form in the initial stages of folding between contacting residues, which 
allows rapid formation of native structure. Others may generate folding 
intermediates, which eventually will be reorganized to form the native 
conformation. 
 
1.1.3. Protein misfolding diseases 
Protein folding in vivo is of remarkably high fidelity, but sometimes defects 
can occur resulting in protein misfolding. In the 1990s, scientists started to 
understand that protein misfolding is involved in the development of many 
diseases (Table 1-1). Protein folding diseases can be divided into two groups. In 
the first group, excessive quantities of misfolded proteins aggregate forming 
amlyoid plaques, a hallmark of amyloidoses, such as Alzheimer’s and 
Creutzfeldt–Jakob diseases (14). In the other group, genetic mutations lead to 
incomplete folding of a protein, which affects its function. This might, for instance, 
happen to the tumor suppressor p53, the loss of function of which results in 
cancer (14). 
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Table 1-1: Representative protein folding diseases (15) 
Disease Protein 
Site of 
folding 
Hypercholesterolaemia Low-density lipoprotein receptor ER 
Cystic fibrosis Cystic fibrosis transmembrane regulator ER 
Phenylketonuria Phenylalanine hydroxylase Cytosol 
Huntington's disease Huntingtin Cytosol 
Marfan syndrome Fibrillin ER 
Osteogenesis imperfecta Procollagen ER 
Sickle cell anaemia Haemoglobin Cytosol 
α1-Antitrypsin deficiency α1-Antitrypsin ER 
Scurvy Collagen ER 
Alzheimer's disease Amyloid α-peptide/tau ER 
Parkinson's disease  α-synuclein Cytosol 
Scrapie/Creutzfeld-Jakob 
disease Prion protein ER 
Familial amyloidoses Transthyretin/Lysozyme ER 
Retinitis pigmentosa Rhodopsin ER 
Cataracts Crystallins Cytosol 
Cancer p53 Cytosol 
 
The common characteristic of all amyloidoses is the collection of plaques 
(amyloids) of insoluble protein in the extracellular tissue, which cannot be 
degraded by proteases. Their structures are highly ordered and give them 
crystal-like properties. Beta-pleated sheet of identical proteins are densely 
packed and form long filaments (fibrils). About 20 different proteins can associate 
with different diseases with unique features (16). The plaques can be transported 
through the bloodstream to different tissues forming amyloid deposites, 
systemically. However, the localized amyloids are more important for clinical 
research because they mainly affect the central nervus system, causing 
neurodegenerative diseases.  
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The general mechanism of amyloid formation reveals that polypeptide 
chains can adopt multiple conformational states and interconvert between them 
on a wide range of time scales. The network of equilibria, which link several of 
the most important states, is schematically illustrated in Figure 1-1. Through 
partially folded intermediates, the protein can compact into a monomer or 
associate to form oligomers or higher aggregates. Oligomers may be functional, 
such as actin, myosin and microtubules. The majority of these proteins will be 
degraded, usually under carefully controlled conditions and as a part of normal 
biochemical processes, with their amino acids often being recycled. However, 
partially folded or unfolded intermediates may enable aggregation (Figure1-1). 
Some of these initial aggregates simply dissociate, while others may reorganize 
to form stable oligomers, initiating amyloid structures (15).   
Transmissible spongiform encephalopathies (TSEs), which include mad 
cow disease (bovine spongiform encephalopathy, BSE) and Creutzfeld Jakob 
disease (CJD) in humans, are special forms of amyloidoses in which the victim’s 
brain degenerates to a structure that looks like a porous sponge. These 
conditions seem to occur when normal protein particles called prions misfold. 
The normal prion is also called PrPc, a component of the membrane of healthy 
nerve cells. When it is properly folded, it remains soluble and degradable. 
However, when it is misfolded in a particular way, it can take on an infectious, 
incorrectly folded three-dimensional form (PrPsc) (17, 18). The infectious prion 
can be transmitted in the diet and trigger a domino effect in healthy prion, forcing 
it to adopt its incorrectly folded form. 
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Figure 1-1: A schematic representation of the protein conformational states that are 
in interconversion. The transition from β-structured aggregates to amyloid fibrils can 
occur by addition of either monomers or protofibrils (depending on protein) to 
preformed β-aggregates. Many of the various states of proteins are utilized 
functionally by biology, including unfolded proteins and amyloid fibrils, but 
conformational diseases will occur when such regulatory systems fail, just as 
metabolic diseases occur when the regulation of chemical processes becomes 
impaired (6). 
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 Another group of protein folding diseases is caused by lack of a correctly 
folded protein. Protein p53 occupies an important position in the cancer 
resistance network. Normally, the p53 system is switched off or in stand-by 
mode. But when the cells become stressed or damaged, p53 is activated to 
prevent genetic mutations, which can cause tumor formation marked by 
uncontrolled division and proliferation of cells. Mutations of p53 gene lead to 
misfolding of p53 and allow abnormal cell growth in an uncontrolled manner (19). 
This type of mutation in p53 is thought to occur in 50% of all cases of cancer and 
as many as 95% of all cases of lung cancer (20). 
 
1.1.4. The endoplasmic reticulum-associated folding (ERAF) and the quality 
control (QC) system inside mammalian cells  
The endoplasmic reticulum (ER) is a large, membranous organelle that is 
in physical contact with almost all other organelles inside the cells, including the 
nucleus, Golgi and plasma membrane (21, 22). In the ER, once the primary 
sequence of a nascent protein has been assembled and released from the ER-
associated ribosome through the Sec61 channel, it has to undergo 
posttranslational modification to become fully functional. The main 
posttranslational modifications are the formation of disulfide bonds, conformation 
folding, and protein glycosylation. While folding or assembling, intermediates 
expose their hydrophobic surfaces, unpaired cysteines or immature glycans. 
Very high concentrations of chaperone proteins in the lumen of the ER, such as 
oxidoreductases, interact with the intermediates and promote their folding. These 
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chaperone proteins work in concert and form complexes, which efficiently 
process proteins and ensure their proper folding.  
 
1.1.4.1. ER chaperones and folding enzymes (foldases) 
About 333 proteins of the ER protein folding machinery are known.  These 
include the lectins, N-glycan processing enzymes, protein disulfide isomerases, 
prolyl cis-trans isomerases, and the molecular chaperones (23). Table 1-2 gives 
a brief list of these proteins. ER-resident foldases such as lectins (calnexin and 
calreticulin) and the general ER-chaperone BiP play key roles in regulating ER-
associated folding (ERAF) and degradation (ERAD) of proteins and will be 
discussed in detail below. 
The canonical ER lectins are the type 1 membrane protein calnexin and 
the closely related ER luminal protein calreticulin. They are two prominent ER 
chaperones, calcium requiring and involved in processing Glc1Man9 N-glycans, 
which are attached to nitrogen (N) residues on nascent proteins. The N- glycans 
are generated by the action of glucosidase II on the Glc2Man9 glycan after 
processing of Glc3Man9 by glucosidase I, or by UGGT1 mediated addition of 
glucose moiety (Figure 1-2). They serve a wide array of functions including 
stabilizing proteins against denaturation, enhancing solubility, orienting proteins 
within membranes, adding structural rigidity, regulating protein turnover, and 
mediating pathogen interactions (24). 
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Table 1-2: Principal ER chaperones and foldases (12). 
Family Main members Functions 
HSP70 Bip/GRP78 Chaperone 
HSP90 Endoplasmin/GRP94 Chaperone 
HSP40 ERdj1-ERdj7 Co-chaperone 
Lectin Calnexin, Calreticulin Glycoprotein quality control 
 EDEMs 1,2,3 Glycoprotein degradation 
 OS-9, XTPB-3 Glycoprotein degradation 
Glycan processing 
enzymes UGGT Folding sensor 
 ER glucosidases I, II Trims off glucose from N-glycan 
 ER mannosidases Removes terminal mannoses 
Peptidyl-prolyl 
isomerases 
Cyclophilin B, 
FKBP13/23/65 Isomerize peptide bonds 
Ero1 Ero1α, Ero1β Oxidation for disulfide bonds 
Oxidoreductases 
PDI, ERp72, ERp57, plus 
many others 
Disulfide bond formation and 
isomerization 
 
BiP is an abundant ER chaperone.  BiP contains an N-terminal ATPase 
domain, stimulated by ER resident J-domain co-chaperones, of which there are 
seven (ERdj1-7) (25). When BiP binds to ATP, it adopts an open conformation. 
ATP hydrolysis causes BiP to adopt a conformation with higher affinity for 
substrate binding. The ADP-bound closed state of BiP can be re-opened, with 
the help of the nucleotide exchange factors GRP170 and Sil1. BiP is usually the 
first chaperone to bind the nascent chain to facilitate translocation of the nascent 
chain into the ER lumen (Figure 1-2). ERdj1 and 2 regulate the nascent chain 
binding.  BiP is also found in a multi-protein complex that includes several protein 
disulfide isomerases and peptidyl-prolyl cis-trans isomerases such as protein 
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disulfide isomerase (PDI) and peptidyl-prolyl cis-trans isomerases (PPIs), 
respectively (26). The association of chaperones with foldases in protein 
complexes was proposed to direct their activities towards the nascent 
polypeptide chain (27). 
PDI is the primary oxidant of cysteine thiols in the ER, and one of the most 
abundant ER proteins. The expression of PDI is rapidly induced under different 
ER stresses (28), indicating a crucial role for PDI in protein folding quality control. 
Under different microenvironments of reduction potential, it can make (oxidize), 
break (reduce), and re-arrange (isomerize) disulfide bonds.  
PPIs, also called rotamases, catalyze the slow isomerization of Xaa-
proline peptide bonds that are found in both cis and trans in folded protein. 
Proline isomerization has been identified as a rate-limiting step (29). Correction 
of Xaa-proline bond orientation happens when a protein has reached an almost 
completely folded conformation (30, 31). 
 
1.1.4.2. The ER folding machinery 
Proteins destined for the secretary pathway and eventually the plasma 
membrane, have an extra intrinsic signal sequence on the N-terminus that is 
exposed as the protein begins to emerge from the ribosome. The signal 
sequence is first recognized and bound to a signal recognition particle (SRP), 
such as SRP54. SRP binds to translating ribosome and the emerging signal 
sequence with high affinity (32). Once the SRP binds to the ribosome and 
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recognizes the signal sequence, the complex is then transported to the ER 
membrane where it binds to the SRP receptor (SR) (33). The SRP/SR complex 
positions the ribosome over a translocon and the protein being translated enters 
the lumen of the ER as it is being translated (32, 33). The translocon is a 
complex that is composed of the microtubule tethering protein Climp63, the 
oligosaccharyltransferase complex (OST), and glucosidase I (GlucI) (34).  
Upon entering the ER lumen, proteins without N-X-S/T consensus, the N-
glycosylation site, directly undergo the folding process facilitated by BiP, PDI, 
and PPI. However, most secreted proteins are first tagged with N-glycan 
(Glc3Man9GlcNAc2) at N-X-S/T consensus. It has been proposed that the 
glycosyl moieties act as a sophisticated quality control tag for protein folding 
inside the ER. The enzymes glucosidases I and II cleave terminal glucose (Glc) 
residues from newly synthesized N-Glycan. The Glc1Man9 N-glycans are 
recognized by the chaperones calnexin and calreticulin. Calnexin and calreticulin 
with the bound protein disulfide isomerases ERp57 establishes a calnexin cycle 
to accelerate the folding of Glc1Man9 N-glycan protein (35). When the glucose 
residue is cleaved, calnexin and calreticulin are released from the protein. If the 
protein is folded into its proper conformation upon release of the lectins, it is 
sorted into COPII vesicles by cargo recruiting lectins ERGIC53, VIP36, and VIPL 
that reside in the ER to Golgi intermediate compartment, called ERGIC (Figure 1-
2).  
Additional candidate protein has been proposed for cargo sorting. One 
such candidate is the p24 family of type I ER membrane proteins that is highly 
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conserved in eukaryotes (36). They are abundant constituents of the ER and 
COPII vesicles and their C-termini binds to COPII coat proteins (SEC23). 
 
1.1.4.3. ER quality control system  
The integrated process of protein folding and targeted protein degradation 
are known as the ER quality control (QC) system (37). In this system, all proteins 
are subjected to a “primary” quality control check that monitors their 
conformation. A secondary quality control mechanism relies on the intrinsic 
signal of proteins and facilitates their transport, such as the process to send 
misfolded proteins for ER-associated degradation (ERAD). The unfolded proteins 
are retained in the ER. In order to promote a renewed cycle of folding, unfolded 
glycoprotein can be recognized by UDP-glucose:glycoprotein-glucosyltransferase 
(UGGT1) in the calnexin cycle. UGGT1 adds one glucose moiety from UDP-
glucose to the unfolded proteins, which bear high content of mannose (Man9) in 
their N-glycans. By rebinding with calnexin and calreticulin, the misfolded 
proteins re-enter the calnexin cycle and undergo further folding catalyzed by 
ERp57 (38) (Figure 1-2).  
Despite the presence of chaperones, some proteins persistently fail to be 
folded and processed properly, which can lead to the formation of non-
functioning protein aggregates. A 1, 2-mannosidase I will cleave a mannose 
residue (Man) from the oligosaccharides of these proteins (39). This leads to the 
recognition by the ER degradation-enhancing 1, 2-mannosidases-like protein 
(EDEM). Then the glycoproteins are targeted for degradation by ER-associated 
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degradation (ERAD) or the ubiquitin- proteasome system through the disposal 
pathway (40) (37). 
 
1.1.4.4.  ER associated degradation (ERAD) 
ERAD is a process by which misfolded ER proteins are detected and prevented 
from progressing along the secretary pathway by ER-resident factors and 
directed to the translocon for retrotranslocation (or dislocation) into the cytosol, 
where they undergo ubiquitin- and proteasome-dependent degradation (41).  
Acting as “mannose timer”, EDEM (ER degradation-enhancing α-mannosidase-
like protein) is responsible for removing the glycoproteins, which could not be 
productively folded, from the calnexin cycle. Futile recycling of terminally 
misfolded proteins is prevented by EDEM, most likely EDEM3, which 
successively cleaves mannose moieties from the glycan, eventually removing the 
mannose that is normally re-glucosylated by UGGT. In complex with the protein 
disulfide isomerase ERdj5 and BiP (42), EDEM produces Man7 N-glycan with a 
terminal α 1,6-linked mannose, providing the targeting signal for ERAD (43). The 
formation of the Man7 N-glycan is a key step in directing glycoprotein substrates 
for ERAD. The lectin OS9 and the related XTP3-B recognize the Man7 N-glycan 
and bring them to form complex with ubiquitin protein ligase, the Hrd1 E3/SEL1L 
protein, and with the ER HSP90 homolog GRP94 and BiP, which help sequester 
the misfolded protein away from other interactions until retrotranslocation (44). 
Eventually, the misfolded proteins are retrotranslocated, ubiquitinated, and 
degraded by the proteasome.  
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Figure 1-2:  ER quality control of newly synthesized glycoproteins (45).  
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1.1.5. The unfolded protein response (UPR) 
Accumulation of misfolded proteins in the ER triggers the unfolded protein 
response (UPR) that signals compensatory mechanisms to keep ER 
Nascent chains enter the ER lumen through the Sec61 complex and are core 
glycosylated by the oligosaccharyltransferase (OST). The two terminal glucose 
residues are rapidly trimmed by sequential action of the glucosidase I and II (step 1). 
Mono-glucosylated N-glycans mediate the initial association of the folding 
polypeptides with the ER lectin chaperones calnexin and/or calreticulin, resulting in 
the exposure to the glycoprotein-dedicated oxidoreductase ERp57. It is likely that 
most glycopolypeptides are released from calnexin/calreticulin/ERp57 in a native, 
transport competent state (step 2). They are rapidly deglucosylated and partially 
demannosylated (step 3) and eventually sequestered in transport vesicles for export 
from the ER (step 4). For a fraction of newly synthesized glycoproteins, folding is not 
completed in a single round of association with calnexin/calreticulin (step 2a). The 
folding intermediate released from the lectin chaperones is deglucosylated (step 3a), 
but its forward transport is inhibited by GT1. GT1 adds back a glucose residue (step 
4a) only to glycoproteins with nearly native conformation. This second chance of 
binding to calnexin/calreticulin facilitates additional folding attempts which likely 
consists disulfide reshuffling. Glycopolypeptides released from calnexin and 
displaying major folding defects are ignored by GT1 (step 3b). Rather, they attract 
BiP, which are extensively demannosylated and dislocated across the ER membrane 
for proteasome-mediated degradation (step 4b). 
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homeostasis, including up-regulation of ER chaperones and down-regulation of 
protein translation (46, 47) (Figure 1-3).  
The UPR is a highly conserved intracellular pathway that was originally 
discovered in yeast. The proximal sensor of ER stress in yeast is the inositol 
requiring enzyme-1 (Ire1). Ire 1 contains a unique endoribonuclease activity in its 
cytosolic domain, which carries out the unconventional splicing of Hac1 mRNA 
(48). Hac1 mRNA is found constitutively in the cytosol, where its native 
nucleotide sequence is inefficiently recognized and translated. In response to ER 
stress, this transmembrane protein is dimerized and trans-autophosphorylated to 
be activated (49). The activated endoribonuclease on Ire1 splices out a specific 
intron causing a frame-shift in the Hac1 nucleotide sequence. The new 
nucleotide sequence is recognized and efficiently translated into the transcription 
factor Hac1p (48). Hac1p subsequently enters the nucleus and induces the 
genes which aid in folding and degradation of unfolded/misfolded proteins. 
Although there are α- and β-alleles of both IRE1 and ATF6 in the 
mammalian genome, only IRE1 α is expressed in all tissues and only ATF6 α 
signals the UPR. IRE1 α is selectively expressed in intestinal epithelial cells and 
it is not known which genes are regulated by ATF6 α. IRE1 activation elicits an 
endoribonuclease function that induces non-conventional splicing of Xbp1 
mRNA. Splicing of Xbp1 mRNA, the only known splicing substrate of IRE1, 
removes a 26-base intron that alters the translation reading frame to produce a 
highly active bZiP transcription factor that activates genes encoding ER protein 
chaperones, lipid biosynthetic enzymes, and ERAD functions (50-52). Upon 
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release from BiP, ATF6 traffics to the Golgi complex where it is cleaved by the 
S1P and S2P processing enzymes to produce a cytosolic fragment that activates 
transcription of genes providing complementary and overlapping functions with 
those activated by XBP1 which restores productive ER protein folding and 
increases ERAD. Indeed, cells deleted in either Ire1 α, Xbp1 or Atf6 α are 
defective in ERAD (53, 54). 
The UPR plays an important role in functions to regulate a cell’s folding 
capability in response to developmental demands or physiological changes. 
Especially, in cell types with a high secretary load or an ER compartment that is 
uniquely susceptible to stress, the UPR becomes vital for cell survival and 
function (50, 55). In response to the ER stress, UPR proteins act in a coordinated 
fashion to initially decrease general protein translation and subsequently 
increase transcription of genes that encode proteins that aid in both protein 
folding and degradation. Therefore, pathological conditions interfering with ER 
homeostasis and resulting in prolonged activation of the UPR could lead to 
various diseases (56, 57). 
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Figure 1-3: Signaling the unfolded protein response (UPR) (58). 
The UPR in mammalian cells is far more complex than that in yeast and appears to 
act both at the level of transcriptional as well as translational regulation (3). 
Mammalian cells have three ER membrane bound proximal sensors. They are the 
mammalian homologue of yeast IRE1, protein kinase R like ER protein kinase 
(PERK), and activating transcription factor 6 (ATF6) (Figure 1-3) (4, 5). The three 
UPR sensors are maintained in an inactive state through interaction with the protein 
chaperone BiP. It is proposed that as unfolded proteins accumulate, bind, and 
sequester BiP, they promote BiP dissociation from PERK, IRE1, and ATF6 (1, 7). BiP 
release from IRE1 and PERK permits their homodimerization, trans-
autophosphorylation, and activation. Activated PERK phosphorylates the α-subunit 
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1.2.    Protein expression and refolding technologies 
Biomedical and structural biology studies of proteins require large quantities 
of purified proteins. Over the past several decades, protein expression systems 
(Escherichia coli, baculovirus-mediated insect cell, Saccharomyces cerevisiae 
and several mammalian based systems) have been developed for large-scale 
recombinant protein expression. Each of these systems has its strength and 
weakness (yield, proper folding, post-translational modifications, etc).  
 
1.2.1.   Prokaryotic expression system 
Escherichia coli is the simplest and by far the most widely used organism 
for protein expression.  Our lab also developed a very high yield bacterial protein 
expression system that produce nearly gram quantity of pure recombinant 
proteins from one liter of bacterial culture (59). Many recombinant proteins have 
been successfully produced in bacteria; however, reports note that ectopically 
expressed proteins especially those that are cystein-rich, have basic isoelectric 
points (pI), and that are less than 10 kDa or greater than 50 kDa have overall 
reduced success rates in traditional purifaction schemes (60).  Other factors such 
of the translation initiation factor 2 (eIF2 ), leading to rapid and transient inhibition of 
protein synthesis (1). eIF2 is a heterotrimeric GTPase required to bring initiator 
methionyl tRNA to the ribosome for AUG initiation codon selection (2). 
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as improper folding, protein aggregation (inclusion body formation), and lack of 
proper eukaryotic post-translational modifications (PTMs) of the ectopically 
expressed proteins could potentially affect their conformation, stability, and 
function.  All of these possible limiting factors reduce the usefullness of bacterial 
protein expression systems, especially for eukaryotic proteins where the success 
rates are typically lower (61-64). 
 
1.2.2. Eukaryotic expression system 
The yeast strain, Saccharomyces cerevisiae is an expression system that 
has the advantage that can produce proteins in a more native eukarytoic 
environment but with reduced yield, a common drawback of eukarytoic 
expression systems.  Another drawback is the S. cerevisiae glycosylation 
pattern, which is very different from its mammalian counterpart, and commonly 
involves hypermannosilation that potentially affects the proper folding and activity 
of heterologously expressed mammalian proteins. 
Insect cell is another common recombinant protein production system. 
Appreciated advantages of insect cells are the robust and relatively inexpensive 
cell culture and the fact that most eukaryotic PTMs are executed properly (65). 
However, the baculovirus expression system requires multi-step process to make 
the viruses and the need to maintain high virus titers which sometimes can be 
quite challenging (66). Furthermore, the protein expression yield of this insect cell 
system is low. 
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For expressing physiological proteins, including therapeutic proteins, 
mammalian cell lines, such as CHO or HEK293, are widely used because they 
offer a cellular environment closer to the native condition. However, the yield of 
this system is quite low. The expression levels of purified recombinant protein are 
usually in the microgram quantity (67) and expression cost of mammalian cell 
protein expression is quite high. This expression system weighs the fidelity of 
PTMs, correct folding and processing in mammalian cells against their slow 
doubling rates, potentially inefficient transfection, overall lower productivity and 
their dependence on expensive reagents, such as serum (68).  
 
1.2.3. Protein refolding in vitro  
Protein studies and protein therapeutics need large quantities of properly 
folded and biologically functional proteins. Genetic engineering allows rapid and 
reliable production of heterologous proteins via recombinant methods, in 
particular, bacterial expression methods. These methods are used to induce cells 
to overexpress a target protein. Overexpressed proteins, however, often form 
“inclusion bodies”, the macroscopic aggregates in cells, especially for the 
prokaryotic expression system. Therefore, the ultimate success of 
overexpression strategies sometimes depends on the refolding rate of properly 
folded native states of aggregated proteins in the bacterial inclusion body. 
Therefore, protein refolding in vitro is important. 
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The first milestone to explore protein refolding in vitro emerged when 
Christian Anfinsen and his colleagues in the 1960s demonstrated that simply 
removing denaturant is sufficient for a fully denatured protein to refold (69). This 
work demonstrated that all the driving forces and guiding information are 
embedded in the primary amino acid sequence of a protein and no external 
template is required. Also, this study showed, just like other processes in nature, 
protein folding needs energy, a process following the universal thermodynamics 
law. Intrinsic protein refolding steps include secondary structure formation, long-
range tertiary contacts, interaction of hydrophobic groups, interaction of hydrogen 
bond donor/acceptor, side-chain packing, and other processes. Conformational 
entropy and several major interactions, such as the hydrophobic effect, hydrogen 
bonds, electrostatic interactions, and van del Waals forces, contribute to protein 
refolding.  
Conformational entropy is the major energy term opposing protein folding 
because entropy is a measure of the degree of randomness or disorder in a 
system. As the folding reaction proceeds, the conformational entropy eventually 
decreases as the unfolded state of protein has the highest conformational 
entropy, whereas the folded protein has the lowest conformational entropy. The 
loss of entropy starts to be compensated by the favorable hydrophobic and other 
interactions.  
Based on the theory, a protein always folds into the conformations, which 
achieve the lowest possible energy. An energy landscape of protein folding 
(Figure 1-4) provides a statistical description of the folding process. It proposes 
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that proteins fold in an ordered way and the whole structure ensemble process is 
an energy-biased folding pathway (70-72). However, this funneled energy 
landscape theory fails to provide clues as to the guidance to the folding reaction 
happening inside living cells. Even though the folding reaction can proceed 
through a multitude of distinct routes to reach the lowest energy native state as 
described in the energy landscape theory (73-77), proteins do not find their 
native conformation from an endless number of potential three-dimensional 
probabilities that it could randomly fold into. The protein folding process in living 
organisms occurs in a second time scale (78). Localized interactions with 
molecular chaperones and enzymes inside of cells guide and speed up the 
folding process.  
 
Figure 1-4: The energy landscape depiction of protein folding (72) .  
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1.2.4. In vitro protein refolding techniques  
 Protein misfolding frequently happens when expressing recombinant 
proteins in a foreign cell as well as inside mammalian cells under certain 
physiological conditions. Experimental approaches have been developed to 
refold aggregated proteins into their biologically active forms. The following 
briefly summarizes these protein refolding techniques: 
 
1.2.4.1.  Direct dilution 
 The simplist of these procedures is the direct dilution method.  Diluting the 
protein reduces intermolecular interactions, denaturants, etc. that could 
contribute to protein aggregation.  However, a major drawback of this technique 
is that the protein is highly diluted and needs to be concentrated.  Concentrating 
may contribute to the reaggregation of the protein.   
 
1.2.4.2.  Dialysis 
 Similar to the direct dilution technique, dialysis can remove potential 
denaturants allowing the unfolded protein to achieve its native conformation. In 
contrast to the direct dilution method, the change from denaturing to native buffer 
conditions occurs gradually allowing the protein to slowly reach its native state.  
However, through this process the unfolded protein may pass through several 
different folding intermediates, some of which are unproductive and even could 
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protentiate protein-protein interactions promoting aggregation (79).  As the 
protein concentration remains relatively stable during this procedure, a potential 
benefit; however, may contribute to promoting the aggregation and thus making 
protein aggregation a frequent problem of dialysis as compared to the direct 
dilution method. Additionally, refolding yields can be negatively affected by non-
specific adsorption of protein to the membrane. However, for some proteins and 
with the appropriate denaturant removal rates, adapted to the requirements of 
the target protein, high refolding yields at high protein concentrations can be 
obtained (80). 
 
1.2.4.3.  Chromatographic methods for protein refolding 
1.2.4.3.1.  Protein refolding based on size exclusion chromatography 
 Similar to both the direct dilution method and dialysis, buffer exchange for 
denaturant removal can also be carried out using size exclusion chromatography 
(SEC). SEC has several major advantages.  The denaturant can be gradually 
removed through use of a concentration gradiant allowing the denatured protein 
to refold.  As with dialysis, protein aggregation can be a problem.  However, the 
power of SEC allows enrichment of the properly folded protein over the mis-
folded/aggregated intermediates by taking advantage of the mobility differences 
based on size, shape, etc. of the target versus the folding intermediates.  
Additionally, SEC also allows concomitent concentration and purification of the 
folded protein.  However, reduced yield of the folded protein, due to aggregation, 
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could occur.  Also, the success of SEC depends on the properties of the 
chromatographic resin to allow efficient separation of the renatured target protein 
from different folding intermediates, misfolded protein, and aggregates that might 
form during the refolding process (81). 
 
1.2.4.3.2.  Assisted protein refolding using affinity chromotography 
 In this technique, the unfolded protein is attached to a solid support 
(matrix material of the column) through a variety of methods such as ‘tagging’ the 
protein (eg. Histidine tag) or using ion-exchange or hydrophobic chromotography  
based methods if the biochemical properties of the protein are known. Proteins 
containing artificially engineered peptide tags such as the hexahistidine tag can 
bind to immobilized metal ions.  After binding, the matrix-protein complex is 
brought to refolding conditions by replacing the denaturing buffer condition with a 
native one. Finally, the refolded protein can be detached from the matrix, e.g. in 
the case hexahistidine-tagged proteins by elution with EDTA or imidazole or by 
buffers with high ionic strength in the case of proteins bound by ionic interactions 
(82). Due to the selective binding, matrix-assisted refolding can combine the 
renaturation of the target protein along with its purification (83).  However, 
copurification of the aggregated/mis-folded proteins side-by-side with the 
refolded protein could occur and may become representative.  If predominant, 
these aggregated/misfolded proteins could interfere in strutural studies and thus 
need to be removed and the purification can be accomplished with SEC. 
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1.2.4.3.3.  Refolding using hydrophobic interaction chromatography 
 Hydrophobic interaction chromatography (HIC) has also been successfully 
used for protein refolding with concomitant removal of contaminating proteins 
during the renaturation process (84). Unfolded proteins are applied to the column 
at high salt concentrations and refolded and eluted with a decreasing salt 
gradient.  It has been proposed that refolding is facilitated during HIC because 
unfolded proteins adsorb at high salt concentrations to the hydrophobic matrix 
and, thus, are not prone to aggregation. Additionally, hydrophobic regions of the 
protein that adsorb to the HIC matrix form micro domains around which native 
structure elements can form. During migration through the column, the protein 
will pass through several steps of adsorption and desorption, controlled by the 
salt concentration and hydrophobicity of the intermediate(s), resulting finally in 
the formation of the native structure (85). 
 
1.2.4.4.  Physical conditions and chemical additives that influence protein 
folding 
 Several physical variables, such as temperature, pressure, and solution 
phases, can impact protein folding.  Temperature has general effects on the rate 
of protein folding.  In general, higher temperatures increasing the rate of folding 
but also the propensity towards aggregation whereas lower temperatures reduce 
the folding rate and can increase the amount of properly folded proteins (86).  
For example, growing bacteria at temperatures slightly lower than 37°C during 
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the protein induction phase can reduce inclusion body formation (and hence 
aggregation) for some proteins (87). 
 Another physical property affecting protein folding is pressure.  Protein 
aggregation can actually be reversed by increasing pressure up to 3 kbar.  
However, above 5 kbar the benefit may be lost as a loss in secondary structure 
may occur (88).  Slowly reducing the pressure back to ambient condition may aid 
the folding process (89, 90).  
At some point, in vivo, some proteins, such as integral membrane 
proteins, come into direct contact with or are transported through lipid 
membranes (91).  Detergents and phospholipids, in the form of micelles and 
liposomes can aid protein refolding in vitro by mimicking the effect of a bilayered 
membrane.  Such methods can solubilize purified membrane proteins enabling 
their proper folding.  Interestingly, in an alternative approach, denatured 
hydrophilic proteins can be forced to fold as independent units in a reverse 
micelle-type system.  Once transferred to this solution, the protein tries to avoid 
the organic phase. After reaching the hydrophilic core of the reversed micelle, 
proteins can refold as a single molecule (92).  Both the micelle and reverse 
micelle approaches aid protein folding of integral membrane and hydrophlic 
proteins, respectively, mainly be preventing unwanted intermolecular protein-
protein interactions that can lead to aggregation.  
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1.2.4.5.  In vitro approaches to fold proteins containing disulfide linkages  
 Folding proteins that harbor disulfide bonds require special considerations.  
Reducing agents such as dithiothreitol or β-mercaptoethanol must be added in 
order to break the incorrect disulfide linkages.  Slowly removing the reducing 
reagent, such as during dialysis or direct dilution, can enable the protein to 
sample several different disulfied linked states until the most stable one (native) 
is found.  Although this method works well for proteins with few disulfide bounds, 
proteins with multiple cysteine residues require special considerations as 
incorrect stable interactions are more likely to occur.  For example, the ligand-
binding domain of apolipoprotein E receptor 2, which has 42 cysteine residues, is 
extremely difficult to refold in vitro (93).  Similar to the in vivo environment, 
approaches utilizing protein chaperones to aid in the folding of multiple disulfide 
linked proteins has found some promise in folding these difficult proteins.  Protein 
disulfide isomerase (PDI) is a folding catalyst that assists disulfide bond 
formation in vivo and has found success for aiding disulfide bond formation 
during in vitro protein folding. Although PDIs significantly increase the refolding 
rate, much of the protein may still not be properly folded (albeit much improved) 
resulting in reduced recovery of the properly folded protein.  Additionally, residual 
concentrations of chaotropic agents in the refolding buffer, especially 
guanidinium hydrochloride, drastically reduce PDI activity and hence the protein 
yield (94, 95). 
Although attempts have been made to mimic the in vivo environment to 
enable protein folding in vitro, the in vivo environment is still ideal.  
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Overexpressing proteins in bacteria and refolding the proteins in vitro may 
produce greater yields; however, some eukaryotic proteins cannot be refolded 
with this approach.  Alternatively, in an eukaryotic environment, these proteins 
can be properly folded (aided by the eukaryotic folding machinery, 1.1.3.) but at a 
dramatically reduced yield.  For this reason, our lab has created a novel protein 
delivery method that takes advantage of the high yield of the bacterial and the 
high fidelity of the eukaryotic expression systems to refold difficult proteins, such 
as the ligand-binding domain of apolipoprotein E receptor 2, to their native 
structure. 
 
1.3.    Protein delivery technology 
Protein delivery techniques deliver biologically active proteins inside live 
cells for cell biology studies and therapeutical applications. The most popular 
means to deliver proteins into cells include electroporation, microinjection, the 
construction of viral fusion proteins, and the use of cationic liposome.  
Electroporation was initially used to introduce foreign DNA into eukaryotic 
and bacterial cells (96). Scientists later found that  proteins could also be 
introduced into cells using the same method (97-99). Cells are electroporated in 
a buffered solution harboring the purified protein of interest. High-voltage electric 
pulses result in the formation of small pores in the cell membrane. Proteins enter 
the cell via these small pores or during the process of membrane reorganization 
as the pores close and the cells return to their normal state. The efficiency of 
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delivery depends upon the strength of the applied electrical field, the length of the 
pulses, temperature, and the composition of the buffered medium. Although this 
method is successful with a variety of cell types, it has a few major drawbacks.  
The overall yield of the protein after repurification from the transduced cells is 
often negligible and the process can be damaging, causing cell death. 
Another method used in the delievery of macromolecules (protein or nucleic 
acid) into live cells is microinjection.  Microinjection was originally used to 
introduce DNA directly into the nucleus of a cell where it can integrate directly 
into the host cell genome, creating an established cell line bearing the gene of 
interest (100). Proteins, such as antibodies and mutant proteins, can also be 
directly delivered into cells via microinjection inorder to determine their cellular 
effects (101, 102). This method has the advantage of directly introducing proteins 
into specific cellular compartments; thereby, bypassing and preventing exposure 
of the delivered protein to extreme microenvironments found within various 
cellular compartments, such as the low-pH endosome. However, microinjection 
requires extensive training and specialized equipment, which is normally not 
available in most laboratories. 
Several viral proteins or peptides have the ability to travel through cell 
membranes independent of classical receptor- or endocytosis-mediated 
pathways.  Membrane fusion proteins, such as the HIV-1 TAT proteins, the 
herpes simplex virus 1 (HSV-1) DNA-binding protein VP22, and the Drosophila 
Antennapedia (Antp) homeotic transcription factor, have the ability to penetrate 
through the plasma membrane and into cells (103). The small protein 
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transduction domains (PTDs), also known as cell-penetrating peptides (CPPs), 
from these proteins can be fused to other proteins of interest to aid their delivery 
into cells (103). Sequence alignment of the PTD shows a high basic amino acid 
content (Lys and Arg), which may facilitate interaction of PTD with negatively 
charged lipids on the cell surface. The advantage of this method is that protein 
entry is rapid and works with many cell lines (104). However, the drawback to all 
of the PTD-mediated protein delivery systems is that the transduction domain 
must be covalently attached to the protein being delivered.  Thus, it is necessary 
to design special vectors and limit the size of the cargo protein because of the 
relatively large PTDs. Also, denaturation or inactivation of proteins was observed 
after PTD fusion, especially for TAT.  Reduced yield after re-purification of the 
PTD protein fusion can also be a major problem since degredation can occur if 
the PTD-fused protein is misfolded, thus significantly reducing the delivery 
efficiency. Furthermore, the PTD-based protein delivery method does not have a 
targeting capability and cannot specifically delivery a protein into the desired 
intracellular compartment, raising concern about the physiological relevance of 
the delivered proteins (104). 
Liposomes are known for their ability as vehicles to deliver macromolecules 
into cells (105, 106). Cationic liposome can spontaneously and efficiently form 
complexes with negatively charged cargo, facilitating the delivery. This strategy 
has been successfully applied to protein delivery (107). But the physical 
characteristics of the cargo, such as the electric charges and hydrophobicity, can 
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influence the extent of the interaction between the cargo and the cationic 
liposome and ultimately impact the delivery efficiency. 
Our lab recently developed an innovative protein delivery technology, based 
on the QQ-reagent, a polyethylenimine (PEI)–based cocktail, with a unique 
formulation of lipids and enhancers (Figure 1-5).  It is compatible with most types 
of cell culture media and non-covalently binds the protein cargo of interest. This 
protein delivery technology is rapid and straightforward.  The protein of interest 
can be produced by highly efficient E. coli expression systems and purified under 
denaturing conditions from inclusion bodies.  The QQ-cocktails can efficiently 
dissolve the target proteins in delivery buffer that contains urea and modify them 
for protein delivery. Another important advantage of QQ-protein delivery 
technique is that it can deliver labeled protein inside mammalian cells, which 
makes in vivo NMR and fluorescence studies potentially possible. More 
importantly, the QQ-protein delivery technique has several novel features that 
significantly distinguishes it from all the other protein delivery techniques 
currently available (Figure 1-5) The novel features of the QQ-protein delivery 
technique ensure the physiological relevance of the delivered proteins, which is 
indistinguishable from the endogenous proteins. Thus, the QQ-protein delivery 
technique can have many applications in cell biology. 
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Figure 1-5: The technical flow-chart of the QQ- protein delivery system. 
 
1.3.1. The QQ-reagent 
        Dr. Qianqin Li in our lab recently develoed a very efficient QQ- protein 
delivery system (the following data on QQ- reagents were done by Dr. Qianqian 
LI). In this protein delivery system, the QQ- reagent plays the key role. It is a 
cocktail of polyethylenimine (PEI) with unique combinations of lipids and 
enhancers. Table 1-3 shows examples of different formulations of the QQ-
reagent. The mechanism of protein delivery by QQ-reagent is unclear. However, 
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PEI is well known for its efficient binding to negatively charged DNA and 
mediating the transfection of eukaryotic cells (108). PEI is highly basic harboring 
many amino groups. The amino groups are protonated at neutral pH and non-
covalently bind negatively charged macromolecules to form a cationic complex. 
The cell surface is normally negatively charged due to the presence of 
glycoproteins, proteoglycans, and sulfated proteoglycans (109-111).  These 
features can mediate interactions between the cell membrane and the cationic 
complex and promote uptake of the QQ-modified proteins (112, 113). The lipid 
composites and enhancers facilitate the solubility of the delivered proteins, such 
as membrane proteins, and help the formation of delivery vesicles, greatly 
enhancing the delivery efficiency of QQ-reagent protein delivery system.  
Table 1-3: Recipes for different QQ reagents from the stock solution of 
cation reagents, lipids and enhancers (Courtesy of Dr. Qianqian Li).  
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A concentration of 50 ug/ml of the QQ modified protein is optimal for 
relatively high protein delivery efficiency. A mixture of QQ modified protein, 
serum-free medium, and protease inhibitor is incubated with the mammalian 
cells, which have been seeded for 2-5 days to reach 80-90% confluency, for 0.5-
4 hours, application dependent. The cells are extensively washed to remove the 
undelivered protein.  With complete growth medium, the cells are ready for 
further experimentation. 
 
1.3.2.   High protein delivery efficiency  
QQ-protein delivery has been tested using different proteins, covering a 
wide range of molecular weights, isoelectric points (pIs), and solubility, including  
two membrane proteins. Table 1-4 lists the 17 proteins, their properties, and their 
protein delivery efficiency using QQ-protein delivery.  
a.   2 kDa, 8 kDa, 12 kDa, 25 kDa and 60 kDa represent the different molecular 
weights of PEI. 
b.   Total volume is 5 ml when preparing the QQ reagents. We also dissolve the 
protein at a concentration of 0.2-8.0 mg/ml, depending on protein solubility and the 
purpose of the studies. 
c.  In our hand, 2 kDa produces the least cellular toxicity whereas 60K produces the 
most cellular toxicity. 
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Table 1-4: Proteins, their properties, and protein delivery efficiency using 
QQ-reagent protein delivery system (Courtesy of Dr. Qianqian Li). 
 
 Figure 1-6 shows the SDS-PAGE (Left panel) and Western blots (right 
panel) of QQ-modified receptor-associated protein (RAP) that was delivered into 
Hela cells. RAP is an ER resident molecular chaperone of the LDLR family 
members, including apoER2 and VLDLR. RAP binds tightly to the receptors at 
neutral pH, acting as a universal antagonist of the ligand binding domains. It also 
escorts the LDLR family members in the early stage of secretary pathway in the 
ER, reducing premature ligand binding and receptor aggregation. Detailed 
background information will be given in Chapter II.  For now, RAP will be used as 
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an example to demonstrate the efficient protein delivery of the QQ-reagent.  The 
grey arrow shows the protein band of bacterially expressed RAP, while the black 
arrow shows the protein band of RAP in the Hela cell lysate after protein delivery 
(Figure 1-6). Compared with the control Hela cell lysates (without protein 
delivery) (lane 1), an additional band of roughly 40 kDa was observed in the Hela 
cell lystes (lanes 2 and 3) of cells preincubated with QQ-modified RAP.  The 
Western blot (Right panel) confirms that this band corresponds to RAP (compare 
lane 1 (control) to lane 2).  In addition, the band intensity of lane 2 was estimated 
to be at least twice as strong as that of lane 3, where 0.25 mg/ml of purified 
bacterially expressed RAP was loaded. This suggests that at least 0.5 mg/ml of 
the QQ-delivered RAP was recovered, demonstrating the efficiency by the QQ-
reagent. 
 
Figure 1-6: High protein delivery efficiency of QQ-reagent modified proteins 
(Courtesy of Dr. Qianqian Li). 
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1.3.3. Protection of the QQ-delivered proteins from intracellular protease   
degradation 
 In order to see the stability of QQ-modified protein inside of mammalian 
cells, MESD, a 195-residue specific protein chaperone for the LDLR family (114) 
(115), was QQ-modified and tested for stability against protease degradation by 
adding protease cocktail into MESD solution (Figure 1-7), which is either 
modified without (lanes 1-4) or with (lanes 7-10) the QQ-reagent.  As compared 
to without protease treatment (lane 5), the protein modified with the QQ-reagent 
(lanes 7-10) showed significantly less degredation as compared to the absence 
of the QQ-modification (lanes 1-4).  These results suggest that the QQ-reagent 
can protect MESD from protease degradation and theoretically from intracellular-
mediated degradation.  Basically, the QQ-reagent may protect the modified 
protein from degradation upon entering into the cell; however, the underlying 
Left: A 10% SDS-PAGE quantitatively showing high efficiency of the QQ-delivered 
RAP. Lane 1: Hela cell lysate without RAP delivery. Lane 2: 5 ul Hela cell lysate with 
RAP delivery for 1 hour. Lane 3: 10 ul Hela cell lysate with RAP delivery for 1 hour. 
Lanes 4-7: 60, 120, 250 and 500 ug/ml of RAP (20 ul). Right: A Western blot using an 
anti-RAP antibody. Lane 1: Hela cell lysate without RAP delivery. Lane 2: 5 ul Hela 
cell lysate with RAP delivery. Lane 3: 0.25 mg/ml bacterial expressed RAP in 5-ul. 
Gray arrow: the bacterial expressed RAP. Black arrow: the HeLa cell loaded RAP. 
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mechanism is not well understood.  This may enable the protein to refold and to 
obtain high yields of repurified protein.    
 
Figure 1-7: QQ-reagent protects MESD from the protease-mediated 
degradation in vitro (Courtesy of Dr. Qianqian Li).   
 
 
1.3.4. Targeting capability of the QQ-protein delivery technique 
 In order to visualize the trafficking of delivered proteins, in this  case 
MESD, a resident ER protein, inside mammalian cells and to detect their final 
location, a small red fluorophore (ArrayIt Red640, Molecular Weight = 799.8 kDa) 
Lane 1-4: MESD without QQ-modification. Lane 7-10: the QQ-modified MESD. While 
reacting with 1.4 mU/ml protease cocktail for 0 hour (Lane 1 and Lane 7), 1 hour 
(Lane 2 and Lane 8), 2 hours (Lane 3 and Lane 9), 4 hours (Lane 4 and Lane 10), 
QQ -modified MESD showed relatively higher stability than the unmodified one. Lane 
5: MESD without reacting with protease cocktail. Lane 6: The QQ-reagent.  
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was linked to MESD. The labeled MESD is modified with QQ-reagent and 
delivered inside of Hela cells.  After 2 hrs post-delivery, MESD is predominantly 
localized to the perinuclear areas, which are potentially the ER (Figure 1-8A). To 
further confirm that this perinuclear localization of MESD was , in fact, to the ER, 
a co-localization experiment was performed. Transient transfection of a GFP-ER 
marker (green) cDNA into BSC-1 cells is conducted following the published 
protocol (116, 117). After 72 hrs, the transfected cells were incubated with QQ-
modified MESD labeled with ArrayIt Red640 (red). After 2 hrs following protein 
delivery, the cells were subjected to fluorescence imaging, showing a merge of 
both the red and green chanels, along with the light microscopy image (Figure 1-
8a). Yellow fluorescence was detected around the perinulear locations, indicating 
MESD was indeed localized to the ER. 
The QQ-reagent was also able to correctly direct the membrane protein 
peripheral myelin protein 22 (PMP22) and the transcription factor Oct4 to their 
appropriate intracellular compartments, the plasma membrane and the nucleus, 
respectivley.  PMP-22 was labeled with the ArrayIt Red640 (red) and delivered 
into Hela cells using QQ-protein delivery. Fluorescence imaging of a Hela cell 
shows that a majority of the red fluorescence signals are localized to the plasma 
membrane (Figure 1-8B and b).  To study intracellular location of the QQ-
delivered Oct4, the bacterially expressed Oct4 was labeled with a small 
fluorophore DyLight 488 (green), QQ-modified, and delievered into human 
fibroblast cells. Fluorescence imaging data showed that the delivered Oct4 is 
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predominantly localized to the nucleus, as it colocalized with the DNA stain, DAPI 
(blue) (Figure 1-8 C and c).  
Taking together, these results show that QQ-reagent delievered proteins 
within the cell as evidenced by the correct in situ residential location of the QQ-
modified MESD, PMP22, and Oct4 to the ER, the plasma membrane, and the 
nucleus, respectivley; otherwise, they would not be localized as such.  This data 
also suggests that the QQ-reagent does not influence the trafficing of these 
proteins.  Also, since these proteins were directed to their correct in situ cellular 
compartments argues that these proteins are likely to be properly folded; 
however, further experiments are needed to confirm this point.  Overall, the QQ-
reagent shows promise as a protein delievery system that can sucessfully 
deliever proteins into cells. 
 
Figure 1-8: Targeting capability of the QQ protein delivery technique 
(Courtesy of Dr. Qianqian Li). 
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1.4. An efficient bacterial expression system that produces gram quantity 
of pure recombinant proteins   
The gram-negative bacterium E. coli offers a means for rapid, high yield, 
and economical production of recombinant proteins. However, high-level 
production of functional eukaryotic proteins in E. coli may not be a routine matter, 
sometimes it is quite challenging. Techniques to optimize heterologous protein 
overproduction in E. coli have been explored for host strain selection, plasmid 
copy numbers, promoter selection, mRNA stability, and codon usage, 
significantly enhancing the yields of the foreign eukaryotic proteins. Our lab has 
(A) Fluorescence confocal image of the intracellular location of ArrayIt Red640 
labeled MESD (red), merging with the light microscopy image of the same HeLa cell. 
The arrows showed the perinulear localization of delivered MESD.  (a) Fluorescence 
confocal image of the co-localization of GFP-ER marker (green) and ArrayIt Red640 
(red) labeled MESD in BSC-1 cells, after QQ-protein delivery.  (B) Fluorescence 
confocal image of a typical HeLa cells after PMP22 transduction. PMP22 was labeled 
with ArrayIt Red640 (red) fluorophore. The arrow showed the plasma membrane 
location of PMP22.  (b) A merging fluorescence confocal image of both Rhodamine 
and CFP channels for the same HeLa cell.  (C) Fluorescence confocal image of 
human fibroblast cell transducted with DyLight 488 (green) labeled Oct4. The arrows 
showed its nucleus localization.  (c) A merging fluorescence confocal image of both 
DyLight 488 (green) labeled Oct4 and nucleus staining DAPI (blue) for the same 
fibroblast cell. 
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been working on optimizations of bacterial expression conditions and media with 
a focus on achieving very high cell density for high-level production of eukaryotic 
proteins. Two high-cell-density bacterial expression methods have been 
explored, including an autoinduction introduced by Studier (118) recently and a 
high-cell-density IPTG-induction method developed in our lab, to achieve a cell-
density OD600 of 10–20 in the normal laboratory setting using a regular incubator 
shaker. Several practical protocols have been implemented with these high-cell-
density expression methods to ensure a very high yield of recombinant protein 
production. With these methods and protocols, a yield of 14–25 mg of NMR 
triple-labeled proteins and 17–34 mg of unlabeled proteins from a 50-mL cell 
culture is routinely achieved for all seven proteins tested. Such a high protein 
yield used the same DNA constructs, bacterial strains, and a regular incubator 
shaker and no fermentor is necessary. More importantly, these methods permit 
for consistently production of such a high yield of recombinant proteins using E. 
coli expression (59). 
 One of the major challenges to achieve high yield protein production is to 
achieve a high cell density bacterial expression under routine laboratory setting 
using a regular incubator shaker. A hybrid bacterial expression method has been 
developed in our lab that utilizes rich medium to achieve a high cell density 
before IPTG induction, while maintaining the advantage of the tightly controlled 
induction by IPTG in minimal medium (59).  This hybrid expression method 
allows us to reach a high cell density with a final OD600 that is 5 to 10 fold higher 
than that of the regular IPTG induction method.  
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 High cell density culture systems, especially under the non-fermentation, 
laboratory conditions, often cause a low or even no protein production with a high 
cell density culture, since bacterial cells experience stress at a high cell density 
using a regular incubator shaker which does not control the O2 level, pH and 
nutrients of the expression medium. To solve this problem, several protocols 
have been developed to ensure stability of plasmids inside bacterial cells during 
high cell-density bacterial expression. These protocols include: (1) Proper 
starting culture; (2) double colony selection; and (3) optimized time course and 
temperature after IPTG-induction (59). In addition, cell areation and medium pH 
during high cell-density expression are also optimized. With these protocols, a 
gram/liter pure recombinant protein is achieved using our bacterial expression 
method. 
 
1.5.    Summary of literature review 
 Protein folding promotes a protein’s native conformation and biological 
function. Misfolding can cause severe protein misfolding diseases, such as 
Alzheimer’s disease, diabetes, cancer, and prion diseases. To study the protein 
folding mechanism, techniques including X-ray crystallography and nuclear 
magnetic resonance spectroscopy (NMR) are critical; however, large quantities 
of properly folded and biologically functional proteins are required. The present 
large-scale heterologous protein expression systems using E.coli, yeast, insect, 
or mammalian cell lines have inherited weaknesses, often causing protein 
misfolding.  In vitro protein refolding techniques are the other option to obtain 
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properly folded and biologically active proteins at relatively high speed and low 
cost. But the efficiency of in vitro protein refolding is greatly affected by the 
aggregation and misfolding reactions happening in the same refolding system. 
Therefore, a more simple and cost-effective protein refolding technique is 
needed. 
Our lab recently developed a novel QQ- protein delivery technique. By 
using the highly efficient QQ-protein delivery technique, we can deliver large 
quantities of bacterially expressed proteins inside of mammalian cells. The QQ-
reagent non-covalently attaches to the delivered protein, efficiently transports the 
protein across the cell membrane, helps the delivered protein to evade 
degredation, and targets the delivered protein to its in situ cellular location.  
Our lab has also developed a highly efficient recombinant protein 
expression method in an E. coli protein expression system. This method bases 
on a hybrid high cell-density IPTG-induction bacterial expression with several 
practical protocols to ensure high-yield production of protein.  This novel bacterial 
expression method allows us to routinely obtain nearly gram quantity of pure 
recombinant proteins from a one-liter bacterial culture. 
 The ER is the cellular machinery of protein translation and protein folding. 
High density of folding chaperones and enzymes exist in the ER, efficiently 
assisting protein refolding. Simultaneously, the stringent quality control (QC) 
system can guarantee only correctly folded proteins are sent to their final 
destinations. By using our developed recombinant protein expression method 
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and QQ-protein delivery technique, we can deliver large quantity of recombinant 
proteins inside of mammalian cells. The ER protein folding machinery may be 
able to refold them with the help of foldases and chaperones. The folded protein 
can be repurified from the cells.  The quality and quantity of purified refolded 
protein can meet the need of many applications, such as structural biology and 
protein therapeutics. 
 
1.6.    Research goals 
 The goal of my dissertation reseach was to develop an in vivo protein 
refolding technique that allows efficient refolding of bacterially expressed proteins 
using the intracellular folding machinery of mammalian cells. The QQ-protein 
delivery technique allows us to deliver the bacterially expressed proteins into the 
ER, where the protein folding machinery of the cell may properly refold the QQ-
delivered proteins efficiently by recruiting chaperones and foldases. The ER 
quality control system ensures that only the properly refolded, bacterially 
expressed proteins will achieve maturity with the misfolded proteins being 
degraded. Thus, this in vivo protein refolding technique may provide an efficient 
strategy to refold large quantity of bacterially expressed proteins that are possibly 
misfolded.  
In particular, this technique may be specifically useful for the efficient 
refolding of secreted proteins, since these proteins will be targeted for secretion 
into the cell culture medium once they are properly folded and posttranslationally 
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modified. Therefore, purification of the refolded proteins will be easy to achieve if 
we use serum-free cell culture medium. In addition, by properly designing the 
protein sequences, we can target protein domains and critical segments of an 
intact protein causing them to be secreted by the cell. Thus, we can take 
advantage of these domains and critical protein segments to allow secretion of 
the protein of interest, which will be already somewhat pure as it is seperated 
from the rest of the cellular millue, making it rather straightforward to efficiently 
refold and purify them in large quantity. Finally, this in vivo protein refolding 
technique may also have the capability to generate properly posttranslationally 
modified proteins inside the ER and Golgi, sites where some posttranslational 
modifications can occur. 
 To develop this in vivo protein refolding technique, two protein domains: 
beta- propeller/EGF domain I of LDL receptor- related protein 6 (BP1-LRP6) and 
the ligand-binding domains of apolipoprotein E receptor 2 (LBD-apoER2), will be 
tested. BP1-LRP6 and LBD-apoER2 are protein domains of two large receptors 
of the low-density lipoprotein receptor (LDLR)-family, with molecular weight of 
34-36 kDa. Both proteins have large numbers of cysteins that form complex 
intracellular disulfide bonds, which are important for their structural rigidity as well 
as their biological function. In particular, LBD-apoER2 contain 298-residues that 
has 42-cysteines, forming 21 intracellular disulfide bonds. This protein domain 
also contains 7 Ca2+-binding sites. Refolding this protein domain is quite 
challenging. Thus, these two protein domains are very good candidates to test 
this in vivo protein refolding technique.  
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Chapter II 
Refolding of the Ligand-Binding Domain of Apolipoprotein E  
receptor 2 (LBD-apoER2) inside mammalian cells 
 
2.1. Introduction  
The aim of this project is to develop and optimize an in vivo protein 
refolding technology that can be used to efficiently refold bacterially expressed 
and potentially misfolded proteins using the ER folding machinery of mammalian 
cells. Previously, our lab demonstrated that the misfolded proteins can be 
delivered into mammalian cells using QQ-protein delivery and these delivered 
protein can be refolded inside of cells. The refolded proteins display biological 
functions and followed the same intracellular trafficking pathways (119). These 
observations provide the solid foundation for this in vivo protein refolding 
technology. 
However, this in vivo protein refolding technique was in its early stage and 
needed to be optimized so that it can be used to efficiently refold large quantities 
of misfolded proteins and to produce properly folded, biologically functional 
proteins. In addition, our optimization also focuses on proteins with complex 
folding since the refolding of these kind of proteins are very challenging and in 
most cases, the in vitro protein refolding techniques cannot be used to properly 
refold these proteins. Our rationale is to utilize the intracellular folding machinery 
of mammalian cells to efficiently refold these challenging proteins. Indeed, cells 
have developed an efficient folding machinery and quality control systems, 
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ensuring that only the proper folded proteins can escape the ER-associated 
degradation system to reach their intracellular destinations or to be secreted 
outside of the cells for function.   
The QQ-protein delivery technique developed in our lab ensures that we 
can efficiently deliver bacterially expressed proteins into the ER for refolding. 
This solved a major problem for this project, since the QQ-protein delivery 
provides us with the targeting capability to specifically and efficiently deliver the 
proteins of interest inside the ER, such that these proteins have a chance for 
refolding. The QQ-reagents are designed to non-covalently bind to the target 
proteins and are hence reversible, enabling the unmodified protein, to have an 
opportunity to be refolded by the ER resident machinery. 
Our lab has been working on low-density lipoprotein receptor (LDLR) 
family for several years.  We are particularly interested in two domains of the 
LDLR family: the ligand-binding domain and the YWTD β-propeller domain, since 
these two domains are the two essential domains for biological functions of this 
protein family. In order to perform research on these proteins, we first used 
bacteria to prepare recombinant domains using the high cell-density bacterial 
expression method recently developed by our lab (59). We found that although 
our bacterial expression method produced large quantities of recombinant 
proteins, these bacterially expressed domains were misfolded and not 
biologically active. This is not surprising since both of the domains contain many 
cysteines that form multiple intramolecular disulfide bonds. In addition, these 
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domains also contain many Ca2+-binding sites. These structural features make it 
very challenging to properly fold these domains. 
However, these two domains of LDLR family provide good candidate 
proteins for us to optimize our in vivo refolding technology. In this chapter, I will 
focus on the refolding technique aimed at refolding the ligand-binding domain of 
apolipoprotein E receptor 2 (LBD-apoER2), an LDLR family member. I optimized 
several different parameters in an attempt to properly fold LBD-apoER2 
including: the best QQ-reagent/LBD-apoER2 ratio for efficient delivery into the 
ER, different cell culture conditions to facilitate refolding, and purification 
procedure to isolate the protein after refolding. Through finding the best 
conditions of this in vivo protein refolding technique, I was able to obtain properly 
refolded LBD-apoER2.  Although the refolding efficiency of the QQ-delivered 
LBD-apoER2 was only up to 20%,  successive rounds of delievery enabled me to 
get large quantitites of protein that I later purified.  Most important of all, I was 
also able to demonstrate that the purified LBD-apoER2 could bind to the ligands 
of apoER2, suggesting that I obtained biologically active and hence properly 
folded protein using this in vivo protein refolding technique. 
 
2.1.1.  LDL receptor superfamily 
Lipoprotein particles mediate the transport of lipophilic molecules in both 
the peripheral circulation system and within the central nerve system (CNS) to 
maintain lipid homeostasis. These particles are typically spherical complexes of 
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lipids and apolipoproteins. They can be recognized by the low-density lipoprotein 
(LDL) receptors located on the cell surface for uptake.  
The low-density lipoprotein receptor (LDLR) superfamily consists of over 
ten known endocytic receptors, all of which share homology with the LDL 
receptor. Most of these receptors are multifunctional, binding and endocytosing 
many structurally and functionally distinct ligands. Together with the LDL 
receptor, these receptors form the LDLR superfamily, primarily owing to their 
structural homology, as well as functional redundancies.  
 
 
Figure 2-1: Domain organization of human LDLR family members (120).  
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Figure 2-1 shows the domain organization of human LDLR-family. All the 
members of the LDL receptor superfamily are composed of five major domains --
- complement-like ligand binding repeats, epidermal growth factor (EGF) –like 
repeats, YWTD β-propeller repeats, a transmembrane domain, and a short 
cytoplasmic tail (121). A primary feature of this family is the presence of cysteine-
rich ligand-binding repeats, which form the ligand-binding domain (122-124). 
These ligand-binding repeats, each of which is about 40 amino acids in length 
and contains six cysteine residues, are also found in a number of complement 
components and are therefore also referred to as complement-type repeats (CR) 
or the LDL receptor type-A (LA) repeats.  
The complex structures of LDLR superfamily members indicate that 
biosynthesis of these receptors must require the assistance of molecular 
chaperones. Indeed, studies with LRP, megalin, and VLDLR have shown that 
RAP serves as a specialized chaperone to assist LDLR superfamily members to 
fold correctly and then traffic safely within the early secretary pathway (125, 126). 
 
Domains characteristic for the LDLR family are discussed in detail in the text. All 
family members have a type I topology (i.e., N-terminus in the ER lumen or the extra-
cellular space and the C-terminus in the cytosol) with the exception of LRP4. The 
cytosolic domains contain one or multiple copies of NPXY, YXXL and di-leucine 
based sequences that mediate internalization and intracellular sorting. 
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2.1.2.  LDL receptor superfamily - structures 
Extensive structural studies have been performed on individual domains of 
LDL-receptor. For the ligand-binding domain, four ligand binding repeat 
structures have been individually solved; only one is by X-ray crystallography, the 
other three are by NMR (127). For example, repeat 1 consists of a beta-hairpin 
structure, followed by a series of a beta turns with many of the side chains of the 
acidic residues, including the highly conserved Ser-Asp-Glu motif, clustered on 
one face of the module (Figure 2-2) (128, 129). Other ligand binding repeats 
display a similar structure with subtle changes (127). The EGF precursor 
homology repeat consists of 392 amino acids; there are three cysteine-rich 
repeats (A, B and C), two at the N-terminus, and one at the C-terminus of YWTD 
β-propeller repeats. In the middle, the YWTD repeats form a six-bladed β-
propeller (Figure 2-2) (130). 
 In 2002, Rudenko et al. determined the crystal structure of the LDL 
receptor domain I and II, residues 1-699, at pH 5.3 corresponding to the ligand-
released state (131) (Figure 2-3). Two histidines (H562, H586) in the β-propeller 
point to repeats 4 and 5, and H190 from repeat 5 protrudes to the β-propeller 
blades. Mutation of the three histidines did not affect the LDL-binding ability, but 
LDL receptor loses its ability to release the bound ligand (132). It was 
hypothesized that within the low pH of the endosome, the ligand-binding domain 
of the receptor dissociates from its ligand, and transforms from its open state to 
the closed state. Repeats 4 and 5 bend to contact the EGF precursor domain via 
their calcium-binding loop (131), and the ligand binding domain flexibility for the  
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Figure 2-2:  Domain organization of the LDL receptor and regions within the 
extracellular domain for which structural information has been obtained (133).  
The O-linked sugar domain is thought to act mainly as a hydrophilic buffer zone that 
keeps bound lipoprotein particles away from the lipid bilayer of the plasma 
membrane. The NPxY motif in the cytoplasmic tail of the LDL receptor is required for 
clustering and internalization. Boxed references next to structural representations 
indicate the cited publication from which the respective structure has been 
reproduced.  
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Figure 2-3: The crystal structure of LDL receptor residue 1-699 at pH 5.3 (131). 
 
 
(A) Cα trace of LDL-R monomer. Modules are colored according to their boundaries 
with the ligand-binding domain containing R2 (residues 44 to 85), R3 (85 to 124), R4 
(124 to 170), R5 (170 to 212), R6 (212 to 254), R7 (254 to 294), and the EGF 
precursor homology domain containing A (294 to 332), B (332 to 377), β propeller 
(377 to 643), and C (643 to 693). Regions of poor backbone connectivity are dashed. 
Calcium ions are indicated as red spheres, and disulfide bonds and carbohydrates on 
Asn135 and Asn251 are shown in gray as ball and stick (sulphur atoms, yellow; oxygen, 
red; nitrogen, blue; and carbon, gray). (B) The view is rotated 90° from that of (A). 
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open-closed state transformation is provided by the linker regions between seven 
repeats instead of the connection of two domain (132). 
 
2.1.3. LDLR superfamily – functions   
 The function that is most commonly associated with this evolutionarily 
ancient family is cholesterol homeostasis. In humans, excess cholesterol in the 
blood is captured by low-density lipoprotein (LDL) and removed in the liver by the 
endocytosis of the LDL receptor (122, 124, 134). Recent evidence indicates that 
the members of the LDL receptor gene family are active in the cell signalling 
pathways between specialized cells in many, if not all, multicellular organisms 
(135, 136).  
 Endocytosis is the process by which cells absorb molecules (such as 
proteins) by engulfing them. The LDLR family plays a critical role in mediating 
this important cellular process (Figure 2-4). The first step of endocytosis is for 
molecules or ligands to bind to LDL receptors exposed at the cell surface. These 
transmembrane proteins have the ligand-binding domain that recognizes and 
binds to the ligands. The portion of the plasma membrane with bound ligand is 
internalized by endocytosis. A drop in the pH (from ~7 to ~5) causes the LDL to 
separate from its receptor. The vesicle then pinches apart into two smaller 
vesicles: one containing free ligands such as LDLs; the other containing now-
empty receptors. The vesicle with the LDLs fuses with a lysosome to form a 
secondary lysosome. The enzymes of the lysosome then release free cholesterol  
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Figure 2-4: LDLR biosynthesis and transport (137).  
 
 
into the cytosol. The vesicle with unoccupied receptors returns to and fuses with 
the plasma membrane, turning inside out as it does so (exocytosis). In this way 
Briefly, LDLR is synthesized by the ER-associated ribosome and is folded inside the 
rough ER and post-translationally modified inside ER and Golgi. The properly folded 
and post-translationally modified LDLR translocates on the cell surface for function. 
Upon binding to LDLR, the LDL-LDLR complex is endocytosed inside the cells via 
clathrin-coated vesicles, which then travels to endosome. The low pH inside 
endosome releases the LDL from LDLR. The released LDLR is recycled back to the 
cell membrane for function, where the LDL is transported to lysosome for 
degradation.  
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the LDL receptors are returned to the cell surface for reuse. Various members of 
the LDLR family display functional similarities (122, 124, 134). 
 One ligand, apolipoprotein E (apoE)-containing lipoprotein, binds most of 
the receptors in the family, suggesting a role in lipid metabolism. Also, most 
members of the LDLR family bind a 39 kDa receptor-associated protein (RAP) 
(138). RAP is an endoplasmic reticulum (ER)-resident chaperone that functions 
in receptor folding and trafficking along the early secretary pathway (125, 138, 
139). Upon binding to the receptors following their translation, RAP promotes 
proper folding and disulfide bond formation for members of the LDLR family. In 
addition, RAP universally antagonizes the ligands binding to the receptors. 
Because this later feature of RAP is believed to be important for escorting the 
receptors and preventing pre-mature ligand binding during their exocytic 
trafficking, the recombinant form of RAP has been extensively used in structural 
and functional studies into the biology of the LDLR family members (138).  
 Recently, several independent studies have also demonstrated roles for 
LDLR family members in cellular signaling (135, 136). For example, cellular 
signaling through the VLDLR and/or apoER2 is important for the Reelin/disabled 
pathway, which participates in neuronal cell migration during embryonic 
development (140). In addition, LRP6 has been shown to be required for the Wnt 
signaling pathway during embryonic development (141-143). Furthermore, a set 
of cytoplasmic adaptor and scaffold proteins containing PID or PDZ domains, 
including mammalian Disabled-1 (mDab1), mDab2, FE65, JNK-interacting 
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protein JIP-1 and JIP-2, PSD-95, CAPON, and SEMCAP-1, binds to the 
cytoplasmic tails of members of the LDLR family (136, 140, 144-146). 
 Members of the LDLR play roles in the pathogenesis of human diseases. 
A classic example is mutation of the LDLR itself in the forms of familiar 
hypercholesterolemia (FH) (147). The crucial role of the LDLR in cholesterol 
homeostasis is indicated by the more than 1500 human mutations that have 
been found in patients with familial hypercholesterolemia (FH) (148, 149). LRP5 
and LRP6 are required for activation of the canonical Wnt signaling pathway for 
cell proliferation and differentiation. Loss of Lrp5 is associated with delayed 
mammary gland development and Wnt1 induced tumorigenesis. Functional 
mutations in the Wnt co-receptor LRP5 also lead to osteoporosis-pseudoglioma, 
while gain of function mutations lead to high bone mass disorders (150-153). 
VLDLR and ApoER2 are obligate components of Reelin signaling pathway 
essential for neuronal migration during development (154, 155). ApoER2 
immunoreactivity in human hippocampus is present exclusively in neurons and is 
increased in Alzheimers Disease (AD) (156). The c-Jun N-terminal kinase (JNK) 
pathway may transduce Aβ neurotoxicity, and apoER2 binds JNK-interacting 
proteins, thus suggesting a possible involvement of apoER2 in AD 
pathophysiology (145). 
 
2.1.4.    ApoER2 
 ApoER2 (apolipoprotein E receptor 2, also called LRP8, is a member of 
the LDLR family (157). It is located on chromosome 1p34 and contains 19 exons, 
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which span a genomic region of about 60 kb (157). ApoER2 is predominantly 
expressed in brain and placenta (158). However, alternative splicing of the 
apoER2 gene transcripts can give rise to different varieties of the apoER2 
proteins from species to species or even from tissue to tissue within the same 
organism.  
 ApoER2 consists of five domains that resemble those of the LDLR and the 
very low-density lipoprotein (VLDL) receptor (157). Expression of apoER2 in 293 
cells demonstrated that it is endocytosis competent (159). However, direct 
comparison of the cytoplasmic domains of LRP, LDLR, VLDLR, and apoER2 
overexpressed in CHO cells suggested a role in signaling rather than in 
endocytosis (160). Studies have shown that apoER2 participates in transmitting 
the extracellular Reelin signal to intracellular signaling processes initiated by 
Disabled-1 (Dab1) (161). Reelin is an extracellular protein essential for the 
development of laminated cortical brain structures in vertebrates (154). Upon 
high-affinity binding to Reelin at the ligand-binding domain, apoER2 transmits the 
Reelin signal to its intracellular domain and this signal underlies learning and 
memory in the adult brain. ApoER2 appears to be the dominant Reelin receptor, 
at least in the forebrain. 
 Later studies showed Reelin binds with high affinity to both apoER2 and 
VLDLR (155, 161, 162), while Dab1 binds to the cytoplasmic NPxY motif of both 
receptors through a PTB domain (144, 146). Importantly, all of the mice deficient 
in both apoER2 and VLDL, or their ligand Reelin, or the adaptor protein Dab1 
show markedly high levels of hyperphosphorylated tau protein, which are found 
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to accompany the formation of the neurofibrillary tangles that are one of the 
pathological hallmarks of Alzheimers Disease (AD) (163). ApoER2 knockout 
mice display disturbed neuronal organization in the hippocampus (164). ApoER2 
immunoreactivity in human hippocampus is present exclusively in neurons and is 
increased in AD (156). The c-Jun N-terminal kinase (JNK) pathway may 
transduce Aβ neurotoxicity, and apoER2 binds JNK-interacting proteins, thus 
suggesting a possible involvement of apoER2 in AD pathophysiology (145). 
 
2.1.5.   Receptor-Associated Protein (RAP) 
 The complex structure of LDL receptors is highlighted by the presence of 
clusters of cysteine-rich, ligand-binding repeats (165, 166). Recent studies have 
shown that, under physiological condition, a 39 kDa receptor-associated protein 
(RAP) RAP serves as a molecular chaperone to assist the lipoprotein receptor 
folding and inhibit pre-mature ligand binding through LDL receptor secretary 
pathway (125, 126). Human RAP is comprised of 323 amino acids. RAP has a 
classical ER-signal sequence, a carboxyl-terminal tetrapeptide (HNEL) that is 
similar to the ER-retention consensus sequence (KDEL) (165, 166). The 
intracellular distribution of RAP was analyzed and quantified, showing 
localization primarily within the ER (70%) and the Golgi network (24%) (167). 
 The most dramatic effect  RAP is the inhibition of binding and/or uptake 
of all other known LRP ligands (168-173). This ability of RAP distinguishes this 
protein from other LRP ligands, which seldom inhibit one another’s binding or 
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uptake. In addition to LRP, RAP also binds to other members of the LDLR 
superfamily and inhibits ligand interactions. Studies have shown that RAP 
exhibits high-affinity binding (KD~1-10 nM) for LRP, megalin, the VLDLR, 
apoER2/LRP8 and LRP11/sorLA-1 (174). But relatively lower binding affinity 
(KD~250 nM) was found for the LDLR (175-179). 
 RAP dissociates from the receptors at the lower pH environment of the 
Golgi, which is consistant with its requirement of binding to LRP and Ca2+ at 
neutral pH (169). Because of the N-terminal KDEL-like consensus, after 
dissociating from receptors in the Golgi, RAP will be recycled back to the ER by 
COPI coated vesicles (Figure 2-5) (139). All these special properties of RAP 
define a novel class of molecular chaperones that selectively protect endocytic 
receptors from ER associated degradation (ERAD).  RAP protects receptors 
such as, the LDLR superfamily, by associating with the ligand binding domain of 
the members of receptors early in the secretary pathway, reducing their ligand 
binding capacity thereby preventing premature ligand-binding induced 
aggregation, and their subsequent degradation in the ER.  Figure 2-5 depicts 
how RAP escorts receptors trafficking from the ER to the Golgi apparatus. 
 
2.1.6.     Challenge of refolding LBD-apoER2 
 It is still unclear how individual domains of LDLR family folds into a 
functional receptor. Disulfide bond formation and calcium incorporation are two 
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dominant characteristics of ligand-binding domain of LDLR (LBD-LDLR) folding in 
the ER. The newly synthesized LBD-LDLR polypeptide chains include seven 
 
Figure 2-5: ER export and retrieval cycle of RAP- Role in LRP secretion (126). 
LDL receptor-related proteins (LRP) are type I membrane proteins that undergo 
cotranslational folding during translocation into the ER. Association with RAP 
prevents premature ligand (Lig) binding in the ER. After transition into Golgi 
compartments, RAP undergoes a conformational change, which is initiated by the 
low-pH-induced charge reversal of histidines (Histidine switch). This partial unfolding 
of RAP may also facilitate its interaction with the KDEL receptor, which mediates the 
retrieval of RAP to the ER. The mildly acidic environment of the Golgi further 
suppresses ligand interaction in the absence RAP, thereby ensuring proper sorting 
and secretion of LRP and cosecreted ligands. 
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ligand binding repeats that were demonstrated to be folded rapidly into compact 
structures, containing non-native disulfide bonds linking distant regions of the 
protein (180, 181). With time, the aid of molecular chaperones, and foldases in 
the ER, the non-native disulfide bonds are reshuffled, allowing extension of the 
molecule. Ultimately, in the native conformation, disulfide bonds only exist 
between cysteine residues within individual ligand binding repeats (131). General 
chaperones recognize and interact with unfolded, partially folded or misfolded 
proteins due to common features such as exposed stretches of hydrophobic 
amino acid residues, thereby preventing aggregation. The relatively oxidizing 
environment of the ER may support disulfide bond formation, but the actual redox 
reactions are catalyzed by oxidoreductases of the protein disulfide isomerase 
(PDI) family (182-184).  
 Incorporation of calcium ions is the second major characteristic of LBD-
LDLR folding. These domains also have very high-affinity calcium binding sites. 
NMR studies on the folding of repeat R5 demonstrated a strict correlation 
between native disulfide bond formation and calcium binding (185). In the 
absence of disulfide bonds, the calcium binding capacity is negligible. When the 
distal disulfide bonds (non-native disulfide bonds) between cysteines II and V, 
and IV and VI are formed, calcium will bind, but maximum affinity requires a 
native structure.  
 Specialized chaperones, RAP and MESD/Boca may facilitate folding of 
different domains of LDLR relatives. Whereas RAP improved the folding of the 
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ligand binding domain of LDLR family (125, 186), MESD/Boca mainly act on 
LDLR containing EGF-like repeats and YWTD β-propeller structures (115, 187).  
 The total seven ligand-binding repeats in the LBD-aopER2 contains 42 
cysteines that form 21 disulfide bonds. Each ligand binding repeat in the ligand 
binding domain (LBD) has three disulfide bonds. In addition, each ligand-binding 
repeat also contains a Ca2+-binding site. Because of the complex array of the 
disulfide bonding formation and Ca2+-binding within the LBD-aopER2, it is 
impossible to refold the protein in vitro into the native conformation, especially 
without the help of molecular chaperones and folding enzymes. Therefore, 
refolding bacterially expressed LBD-apoER2 becomes extremely challenging. To 
our knowledge, only one report claimed successful refolding of the bacterially 
expressed recombinant LBD-LDLR in vitro by dialyzing the protein under redox 
conditions (188).  We made several attempts to refold the structurally similar 
LBD-apoER2 under this published condition but found that this in vitro refolding 
condition could not successfully refold LBD-apoER2 into its native conformation. 
 This problem drove us to explore other methods to refold bacterially 
expressed recombinant LBD-apoER2. We found that our in vivo protein folding 
technology is able to properly refold bacterially expressed apoER2 inside 
mammalian cells. We further optimized this in vivo protein refolding technique 
and achieved up to 20% refolding efficiency. This allows us to prepare milligram 
quantity of properly refolded LBD-apoER2 that is biologically functional. This is 
the main focus of this chapter.   
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2.1.7.   A novel in vivo protein refolding technique 
Our lab recently developed a novel in vivo protein refolding approach to 
efficiently refold large quantities of bacterially expressed proteins into their 
properly folded and biologically functional conformations. This technique is based 
on the fact that the mammalian cells have comprehensive protein folding 
machinery to assist complex protein folding.  
Protein folding in mammalian cells occurs in the ER, an extremely macro-
molecularly crowded environment harboring lots of folding enzymes and 
molecular chaperones (188). Most chaperones, such as the Hsp70s, can 
recognize and bind to hydrophobic residues and/or unstructured backbone 
regions of non-native proteins, not only to block intermolecular aggregation but 
also to prevent or reverse intramolecular misfolding. Folding enzymes, such as 
disulphide isomerases and peptidyl–prolyl isomerases, can catalyze rate-limiting 
steps in protein folding (12).  
Not only does the ER provide a unique folding environment, but it also 
exerts crucial quality control functions (188). Certain chaperones of the Hsp100 
family even have the ability to unfold non-native proteins or to disrupt small 
protein aggregates by an ATP-dependent mechanism. The ATP-dependent 
unfolding is a prerequisite for the proteolytic degradation of misfolded proteins 
(37, 38). Proteins that fail to fold or assemble are not allowed to proceed further 
downstream (to the Golgi). Instead, they undergo ER-associated degradation 
(ERAD).  
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Figure 2-6: The technical flow chart of the novel in vivo protein refolding 
technique developed by our lab.   
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Our refolding method takes advantage of this comprehensive protein 
folding machinery inside mammalian cells by using our highly efficient QQ-
protein delivery technique and the high-yield bacteria expression method. As 
shown in Figure 2-6, first, a very high yield of bacterially expressed proteins is 
achieved by our advanced bacterial expression system. We purify bacterially 
expressed recombinant proteins by affinity chromatography. If the purified 
proteins are not properly folded and functional, we perform the in vivo protein 
refolding procedure.  By using QQ-reagent to non-covalently modify the 
bacterially expressed proteins, we deliver QQ-modified proteins to mammalian 
cells for in vivo protein refolding and post-translational modification. The properly 
refolded protein will be sent to its targeted intracellular compartments or will be 
secreted into the cell culture medium, depending on its intrinsic signal. We then 
lyse the cells or collect the culture medium to purify the properly refolded protein. 
Our biophysical studies and function assay data suggest that the purified 
refolded proteins adopt proper conformations and are biologically functional. 
 
 
The target protein is first expressed in E.coli and then is subjected to affinity column 
purification. The bacterial expressed protein is misfolded. The QQ-reagent modifies 
the bacterial expressed protein and delivers it inside of mammalian cells for protein 
refolding and post-translational modification. Properly folded protein will be purified to 
obtain functional proteins.  
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2.2.     Material and methods 
2.2.1.     Strain, plasmid and media 
 E.coli stain ER2556 [genotype: F − λ − fhuA2 [lon] ompT lacZ::T7 geneI 
gal sulA11 ∆(mcrC-mrr)11::IS10 R(mcr-73::miniTn10)2 R(zgb-210::Tn10) 1 
(TetS) endA1 [dcm]; New England Biolabs] was used for molecular cloning. E. 
coli strain BL21(DE3) [F- ompT hsdSB (rB-mB-) gal dcm (DE3 [lacI lacUV5-T7 
gene1 ind1 Sam7 nin5; New England Biolabs] was used for protein expression 
and purification. LBD-apoER2 with an N-terminal 6-histidine tag was constructed 
using a pET30a-sHT bacterial expression vector which is engineered from 
pET30a (+) (Novagen). 
 
2.2.2. DNA manipulation 
 The original long his-tag of the pET30a (+) vector (Novagen) was 
replaced by a short his-tag containing six histidine plus two serine residues by 
mutagenesis. Mutagenesis was carried out using the QuickChangeTM site-
directed mutagenesis kit (Stratagene, CA). The mutations were confirmed by 
DNA sequencing.  
 LBD-apoER2 was subcloned into the engineered pET30a-sHT vector. The 
confirmed positive DNA constructs were first transformed into E.coli ER2566 
competent cells for plasmid DNA replication and glycerol stock purposes and 
then were transformed into BL21(DE3) cells for protein expression. 
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2.2.3. Protein expression and purification 
Protein expression was carried out using E.coli. BL21 (DE3) cells. A 10-15 
ml overnight culture in a rich medium, such as 2x YT, was made from a glycerol 
stock. Next morning, the overnight culture was diluted into the LB medium with a 
ratio 1:100. The culture was gown in LB medium with 30 ug/ml kanamycin at 37 
°C until it reached an OD 600 of 0.8-1.0. The cells were spun down and re-incubate 
into a minimal M9 medium (kanamycin, 30 ug/ml) at 1:1 volume ratio. The culture 
was continued at 20 °C for one hour. A sample of the cu lture was taken to check 
its OD600 to confirm the continuous growth of cells under lower temperature and 
the minimal M9 medium. Then expression of the recombinant LBD-apER2 was 
induced by IPTG (0.5 mM, final concentration). The culture continued overnight 
at 20 °C.  
The cells were harvested by centrifuge next morning. The cell pellet was 
re-suspended in the binding buffer (10 g/ml cells, 20 mM Tris-HCl, 500 mM NaCl, 
2.5 mM imidazole, 6 M urea at pH 8.0) of His tag affinity purification system and 
sonicated on ice. To separate the cell pellet from the supernatant, the cell pellet 
was centrifuged. The pellet was again re-suspended in the binding buffer with 6 
M urea and sonicated on ice. This procedure was repeated three times to ensure 
that all bacterially expressed LBD-apoER2 in the inclusion bodies was solubilized 
in the buffer system. All supernatant fractions were combined and applied on a 
HisBind® resin column (Novagen). The column was washed with a large amount 
of binding buffer with 6 M urea and the washing buffer containing 20-30 mM 
imidazole for 100-500 ml. The purified recombinant LBD-apoER2 was eluted 
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from the column using the elution buffer with 1.0 M imidazole and 6 M urea. The 
eluted protein was extensively dialyzed against 10 mM ammonium bicarbonate. 
After dialysis, the protein solution was lyophilized and the pure LBD-apoER2 
protein powder was obtained, which was weighed and stored at -20°C for future 
experiments. 
 
2.2.4  Isotope-labeled protein expression and purification 
High cell-density expression method (59) was used to greatly improve 
isotope labeled protein yield at the same time to reduce the costs. The 
transformed cells were inoculated into LB medium for overnight cultures, which 
was then diluted by 100 volume folds into the LB medium at the next morning 
and cultured at 37 °C in the presence of kanamycin (30 ug/ml). When the OD600 
reached around 1.5-2.0, we switched the cell culture to isotope-labeled M9 
minimal medium by gently spinning down cells and re-suspended the cell pellet 
into the medium. Isotope-labeling is achieved by expressing LBD-apoER2 in this 
special isotope-labeled M9 minimal medium, in which NH4Cl is replaced by 0.1% 
15NH4Cl and glucose is replaced by 0.2% 13C-glucose and H2O is replaced by 
D2O for 2H/13C/15N triple-labeled samples, respectively. After switching the 
medium, the cells were cultured for another 1.0-1.5 hours for growth recovery 
and medium exchange at 37 °C. Then 0.8 mM IPTG was ad ded to induce protein 
production. The cell culture was incubated in 20 °C for  overnight expression. The 
cells were harvested next morning. Protein purification was carried out as same 
as unlabeled protein described above. The dialyzed protein solution was 
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lyophilized to get the pure isotope-labeled LBD-apoER2 protein powder. The 
protein powder was weighed and was stored at -20 °C fo r future experiments. 
 
2.2.5       Cell culture 
 HeLa CLL-2 cells were cultured in Dulbecco minimum essential medium 
(DMEM) containing 8% fetal bovine serum (FBS). The cells were maintained at 
37°C in humidified air containing 5% CO 2.  For protein delivery, HeLa CLL-2 cells 
were incubated to reach 80% confluence (about 6x106 cells). 
 
2.2.6. Protein delivery time course 
 5 mg of bacterially expressed LBD-apoER2 was modified using 4 ml of 
QQ-reagent for overnight at 4°C with gental shaking. QQ-reagent contains 15  
mg/ml PEI (1300kDa) at pH8.0. Modified LBD-apoER2 was centrifuged at 5000 
rpm for 5 minutes to remove precipitation. Then the modified LBD-apoER2 was 
mixed with serum-free DMEM to reach the total volume of 50 ml and the final 
protein concentration of 0.1 mg/ml and QQ-reagent at 1.2 mg/ml. 10 flasks (75 
cm2) of 80% confluent HeLa cells were incubated with the protein delivery 
medium and protease inhibitor for 10 hours. Each hour, triplicate samples of the 
protein delivery medium were taken. After 10 hours of incubation with the protein 
delivery medium, the protein delivery medium was removed and HeLa cells were 
gently washed with PBS buffer, three times. Then fresh serum-free DMEM 
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medium was added for another 12 hours. After 12 hours, samples of the medium 
were taken (in triplicate).  All the samples were analyzed further. 
 
2.2.7.  DNA transfection and fluorescence spectroscopy 
The ER-GFP marker DNA (15 ul, 0.5 mg/ml) or Golgi-CFP marker DNA 
(20 ul, 0.5 mg/ml) was mixed with Escort lipid for 2 hours (20 ul, 0.5 mg/ml). The 
mixture was added into 200 ul DMEM cell culture medium and incubated for 20 
minutes at room temperature. This DMEM medium was then mixed with 1 ml 
DMEM containing HeLa cells and 5% FBS and incubated for 3 hrs. The cells 
were washed several times and incubated in a DMEM medium with 10% FBS for 
72 hours before fluorescence imaging. 
The fluorescence spectroscopy was carried out using a PTI QuantaMaster 
QM-7/2003 spectrofluorometer at room temperature, with an excitation at 250 
nm. To deconvolute fluorescence spectra, we carried out synchronous 
fluorescence spectroscopy using a program provided by PTI. In particular, the 
excitation was between 250-500 nm and emission spectra were collected in both 
300-550 and 500-750 nm. 
 
2.2.8.  Detect functional LBD-apoER2 in the time course media by Western 
blotting and ligand-blotting assay 
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2.2.8.1.  Western- blotting 
The recombinant LBD-apoER2 contains His-tag. Equal amount of the time 
course medium samples were subjected to SDS-PAGE under reducing 
conditions. Following transferring to the PVDF membrane, successive incubation 
with mouse anti-His tag monoclonal antibody (Sigma) and horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Amersham Life Science) 
were carried out according to the manufacturer’s specifications. The 
immunoreactive proteins were then detected using the enhanced 
chemiluminescence (ECL) system. 
 
2.2.8.2.  The ligand-blotting assay 
 The ligand-blotting assay can detect and quantify the properly refolded 
LBD-apoER2, while the bacterially expressed LBD-apoER2, which is in non-
native conformation, should give a negative signal. The working principle of the 
ligand-blotting assay lies in the fact that the ligand-binding domain of apoER2 is 
fully functional on nitrocellulose under a physiological relative condition. If LBD-
apoER2 is subjected to such procedure, the immobilized LBD-apoER2 can then 
be visualized and/or quantified following incubation with ligands that can be 
detected by standard Western blotting procedures.  
 The ligand used is the 39 kDa receptor-associated protein (RAP), which 
constitutes a non-lipoprotein ligand with high-affinity (KD~1-10 nM) for the ligand-
binding domain of all known members of the LDL receptor gene family (174). 
RAP is a chaperone for the LDL receptor family members. It associates with the 
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members of the LDLR by binding to newly synthesized and properly folded the 
ligand-binding domain of the receptors, preventing premature ligand-binding 
induced aggregation and subsequent degradation in the ER (125). RAP also 
escorts the receptors trafficking from the ER to the Golgi apparatus. In the ligand-
blotting assay of LBD-apoER2, the advantage of using RAP is the high binding 
affinity between RAP and folded LBD-apoER2 that it is sufficient and easy for the 
detection by standard methods such as western blotting via the His tag of RAP. 
And the insensitivity of RAP to detergents, but not lipoproteins, allows detergent-
containing washes to facilitate cleaner backgrounds. 
Another advantage of the ligand-blotting assay is the whole procedure can 
be conducted under a physiological condition and there is no denaturants to 
disrupt the protein-protein interaction. Traditional far western blot assays need to 
go through steps such as SDS-PAGE gel and transferring step. Fractionating 
protein samples on an SDS-PAGE gel may cause the denaturation of protein 
samples. Transferring protein samples from the gel onto a solid support 
membrane such as PVDF or nitric cellulose membrane is assisted by the transfer 
buffer, which contains denaturant methanol and a relatively high voltage. The 
methanol in the transfer buffer and the heat produced while transferring may also 
denature the protein. These procedures may disrupt protein-protein interaction 
between the properly folded LBD-apoER2 and RAP by denaturing and produce 
false-negative results. Therefore, we skip the SDS-PAGE gel running step and 
the transferring step. We directly dot the PBS solution of LBD-apoER2 onto a 
nitric cellulose membrane (dot blot) and incubate with the probe RAP. Then we 
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apply standard Western blotting procedure to detect the bound RAP and 
indirectly detect our properly refolded LBD-apoER2 in the protein samples 
(Figure 2-7).  
 
 
Figure 2-7: Ligand-blotting assay.  
 
Three ul of samples was dot-blotted onto nitrocellulose membrane. After 
being dried for 30 minutes, the membrane was blocked in 3% non-fat milk PBS 
solution at room temperature for 1 hour with gentle agitation. For probing 
purposes, a 2 mg/ml RAP PBS solution was diluted in 10 ml 3% non-fat milk PBS 
solution to reach the final concentration of 20 ug/ml. After decanting the blocking 
buffer, the membrane reacted with RAP for 2 hours at room temperature. The 
membrane was then washed five times with 20 ml 1x PBS per 5 minutes at room 
temperature. The rabbit anti-RAP (Abnova) antibody was diluted in 3% non-fat 
milk PBS solution at the ration of 1:1000. The membrane was probed with rabbit 
anti-RAP antibody for 1 hour at room temperature with gentle agitation.  The 
membrane was washed as described above. Next, the rabbit anti-RAP-antigen 
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complexes were detected with goat anti-rabbit IgG (HRP-conjugate) (1:10,000), 
followed by ECL detection. A replicated membrane probed with the secondary 
antibody alone did not display any signals (data not shown).  Represenative data 
sets are shown.  For presentation purposes, the squares containing each dot blot 
were arranged in a single column or a row for figures although they were derived 
from the same dot blot. 
 
2.2.9. Refolding of LBD-apoER2 inside of HeLa cells 
 Five mg of bacterially expressed LBD-apoER2 was modified using 4 ml of 
QQ-reagent for overnight at 4 °C with gentle shaking.  Modified LBD-apoER2 was 
centrifuged at 5000 rpm for 5 minutes to remove precipitation. Then the modified 
LBD-apoER2 was mixed with serum-free DMEM to reach the final volume and 
concentration of 50 ml and 0.1 mg/ml of the LBD-apoER2 and 1.2 mg/ml of the 
QQ-reagent, respectively. Ten flasks (75 cm2) of 80% confluent HeLa cells were 
incubated with the protein delivery medium and protease inhibitor for 3-4 hours. 
After protein delivery, the protein delivery medium was removed and HeLa cells 
were gently washed three times with PBS. Then fresh serum-free DMEM 
medium was added for overnight (around 12 hours). The next morning, the 
overnight incubation serum-free DMEM medium, with the secreted and properly 
refolded LBD-apoER2 from HeLa cells, was collected and subjected to 
purification.   
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2.2.10. Purification of the refolded LBD-apoER2 from Hela cells 
  Protein purification of the folded LBD-apoER2 secreated from the HeLa 
cells was performed under native conditions without the use of denaturing 
reagents such as 6 M urea. The folded LBD-apoER2A was diluted into binding 
buffer that contained a high NaCl concentration (1M) to increase its solubility and 
to decrease the non-specific binding of other proteins to the nickel chelating 
column during purification. 
 The collected overnight incubation DMEM medium was 3-fold diluted with 
binding buffer (20 mM Tris-HCl, 1M NaCl and 10 mM imidazole at pH 8.0) and 
then loaded onto a His-bind resin column.  The column was washed with another 
100 ml of binding buffer followed by 100 ml of washing buffer (20 mM Tris-HCl, 
1M NaCl and 20 mM imidazole at pH 8.0). The refolded LBD-apoER2 was finally 
eluted using 100 mM imidazole in a 200 ml volume. The eluate was dialyzed 
against 10 mM ammonium bicarbonate to remove imidazole and salts. After 
extensive dialysis, the elution was lyophilized. The pure refolded LBD-apoER2 
powder was weighed and stored at -20 °C. 
 
2.2.11. Detection of refolded LBD-apoER2 by western-blotting 
The refolded LBD-apoER2 protein powder was subjected to western 
blotting using an anti-His tag antibody (Sigma) and anti-apoER2 antibody 
(Abnova). Equal amount of the refolded LBD-apoER2 and bacterially expressed 
LBD-apoER2 were loaded onto SDS-PAGE gels. Samples were run on the gels 
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under both non-reducing and reducing conditions and then transferred to PVDF 
membranes; duplicate membranes were prepared.  One PVDF membrane was 
incubated with mouse anti-His tag monoclonal antibody  and the other membrane 
was incubated with mouse anti-apoER2 antibody. Both were then probed with 
HRP-conjugated secondary antibodies (Amersham Life Science) according to the 
manufacturer’s specification. The immunoreactive proteins were detected by 
ECL. 
 
2.2.12.  Detection of the biological function of the refolded LBD-apoER2 by 
the ligand-blotting assay 
 The refolded and the bacterially expressed LBD-apoER2 protein powder 
were first dissolved in PBS buffer individually. Three ul of each were dotted onto 
the nitric cellulose membrane with RAP as the positive control. After drying the 
membrane for 30 minutes, the membrane was subjected to the ligand-blotting 
assay (see section 2.2.8.2. for details). 
 
2.3. Results  
2.3.1. Bacterial expression and purification of the recombinant LBD-
apoER2  
 Using our high-yield E.coli protein expression system, large amount of 
recombinant LBD-apoER2 was produced. However, the recombinant LBD-
apoER2 includes 42 cysteines. In the E.coli protein expression systems, these 
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cysteines cannot form proper disulfide bonds as seen in the native conformation 
of LBD-apoER2. They randomly form non-native intramolecular or intermolecular 
disulfide bonds. Most of the time, dimer, trimer or even higher oligomers were 
formed. Large amount of aggregates formed inclusion bodies inside E.coli. We 
used high concentrations of denaturant, such as 6 M urea, to extract the 
expressed recombinant LBD-apoER2. Due to the complicated conformations of 
the bacterially expressed recombinant LBD-apoER2, we normally could not 
detect the expected protein band at its molecular weight of 34 kDa on a 12% 
SDS-PAGE gel. Instead, we frequently detected a slower mobility protein band of 
approximately 50 kDa. This protein band was found only in the whole cell lysates 
of IPTG induced bacterial cells with absence of the reducing reagent, DTT 
(Figure 2-8 left panel, compare lanes 1 and 2).  This suggested that this slower 
mobility band may be the LBD-apoER2. We performed Western blotting to 
confirm that the identity of this protein band (data not shown). 
 The bacterially expressed LBD-apoER2 protein powder was dissolved in 
PBS buffer at the concentration of 0.1 mg/ml. Unexpectedly, the band around 50 
kDa seen in the whole cell lysates induced with IPTG (Figure 2-8 left panel, lane 
1) was no longer detected, instead a diffuse band between 30 kDa and 40 kDa 
was now observed (right panel of Figure 2-8, lane 1). Changing the buffer 
condition or the drying step (lyophilization) could have affected the 
folding/disulfide linkages, thus affecting the mobility.  Though the band was 
running around its expected molecular weight of 34 kDa, it does not mean the 
                                                                               82 
 
 
 
bacterially expressed LBD-apoER2 was properly folded. The band was diffuse, 
suggesting it represents alternative folded states of the protein.  Adding DTT  
 
Figure 2-8: Expression and purification of bacterially expressed LBD-apoER2.  
The left panel is the 12% SDS-PAGE stained with Coomassie blue, showing IPTG 
induced expression of LBD-ApoER2 in E. coli. Whole cell lysates (without DTT) 
induced with (lane 1) or without (lane 2) IPTG are shown.  A protein molecular weight 
marker, lane M, was loaded with the 20 and 50 kDa bands pointed out with arrows for 
reference.  The right panel is a Coomassie blue stained, 12% SDS-PAGE showing 
the eluted fraction from nickel chelating column that contains the purified LBD-
ApoER2. Lane 1, the eluted fraction without DTT, showing a diffuse protein band at 
34 kDa. Lane 2, the eluted fraction containing 10 mM DTT.  The 30, 40, and 50 kDa 
bands of the molecular weight marker (lane M) are indicated for reference. 
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Figure 2-9: Expression and purification of isotope-labelled, bacterially expressed 
LBD-apoER2.  
 
(100 mM) resulted in a single band of greater than 50 kDa (Figure 2-8, right 
panel, lane 2).  DTT could have released the unstable disulfied bonds (diffuse 
character) in the protein and linearized the peptide chains, resulting in greatly 
The left panel is the 12% SDS-PAGE showing IPTG induced expression of isotope 
labeled LBD-apoER2 in the minimal medium containing 15NH4Cl, 13C- glucose and  
D2O. Lane 1, E. coli cell lysates following induction of protein expression. Lane 2, the 
E. coli cell lysates without IPTG induced expression as negative control. The right 
panel is the 12% SDS-PAGE showing the purification using His•Bind column. Lane 1, 
the 1st soluble fraction of inclusion bodies in 6 M urea. Lane 2, the 2nd soluble fraction 
of inclusion bodies in 6 M urea. Lane 3, the flow-through of the lysates after loading 
onto the nickel chelating column. Lane 4, the flow-through of binding buffer wash. 
Lane 5, the flow-through of washing buffer wash. Lane 6, the eluted fraction. Lane 7, 
the eluted fraction in a reaction mixture containing 10 mM DTT. 
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reduced mobility observed (Figure 2-8, Right panel, lane 2).  We repeatedly 
found this characteristic of LBD-apoER2 in the SDS-PAGEs. Therefore, this 
mobility character of LBD-apoER2 with or without DTT on SDS-PAGE provided 
evidence for the bacterially expressed LBD-apoER2.  
 The recombinant LBD-apoER2 in the inclusion bodies of E.coli was very 
difficult to dissolve in the normal nickel chelating purification buffers. Six M urea 
was applied throughout the whole protein purification procedure and was 
removed through dialysis.  A high yield of purified recombinant LBD-apoER2 was 
obtained after the lyophilizing step (50 mg/liter).  In order to perform NMR studies 
of LBD-apoER2, we also prepared isotope labeled LBD-apoER2 (Figure 2-9). 
The protein produced the same character as in the unlabled protein (compare 
Figures 2-8, right panel, lanes 1 and 2 to Figure 2-9, Right panel, lanes 6 and 7).  
The yield of isotope labeled protein was lower than unlabeled protein; however, 
by using the high-yield protein expression system in E.coli, 60.04 mg of isotope 
labeled LBD-apoER2 was obtained for further experiments. 
 
2.3.2. Highly efficient protein delivery by QQ-reagent 
 To refold bacterially expressed LBD-apoER2 inside HeLa cells, we 
delivered the bacterially expressed LBD-apoER2 into HeLa cells for in vivo 
refolding in the ER. Using QQ-protein delivery, we can deliver different proteins. 
However, due to the different biochemical properties of different proteins, an 
optimization step is necessary for an individual protein for efficient protein 
delivery.   
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Figure 2-10: A Coomassie stained 12% SDS-PAGE showing a time course of the 
QQ-protein delivery of LBD-apoER2 into HeLa cells.  
 
Bacterially expressed LBD-apoER2 was modified using QQ-reagent at the 
concentration of 0.1 mg/ml. HeLa cells were incubated with the protein delivery 
medium. Aliquots of the cell culture medium were taken at 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 
and 10 hours and then the protein delivery medium was exchanged for fresh serum-
free DMEM medium for another 12 hours incubation. The protein samples run under 
reducing conditions are shown. Lanes 1-11 were the samples from 0 to 10 hours 
incubation. Lane 12, serum-free DMEM medium sample after another 12 hours 
incubation. Lane 13, the bacterial expressed LBD-apoER2 served as  a positive 
control and positional control for the QQ-modified protein before delievery and is 
essential the same as lane 1 except that the protein in lane 13 is not modified with 
QQ-reagent.  
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 We found that at the concentration of 0.1 mg/ml, the QQ-modified LBD-
apoER2 could be delivered efficiently while HeLa cells maintained their healthy 
morphology. Higher concentrations were also tried. But either higher 
concentration of QQ-modified LBD-apoER2 or higher content of QQ reagent in 
the delivery medium introduced higher cellular toxicity, causing the rapid 
appearance of membrane blebs on the surface of most HeLa cells and 
subsequent apoptosis (data not shown). 
 The QQ-modified LBD-ApoER2 was delievered into Hela cells and 
samples of the cell culture medium containing both the remaining undelivered 
protein as well as secreted protein was collected hourly over  a 10 hour peroid.  
All samples were subjected to SDS-PAGE. Under reducing conditions, focused 
and sharp protein bands of LBD-apoER2 were detectable on SDS-PAGE (Figure 
2-10). The results showed that the protein band (red arrow) density of QQ-
modified LBD-apoER2 was decreased after 3 hours (Figure 2-10, lanes 1-4), 
while a new faint band of faster mobility gradually appeared in the later time 
points (Figure 2-10, lanes 3-11). The slower mobility band that gradually 
dissipates is the original modified protein while the faster mobility band is likely 
the secreted LBD-ApoER2.  After an additional 12-hour incubation with a regular 
cell culture medium that did not harbor modified protein,  neither band could be 
detected and were likely beyond the limit of sensitivity for this method (Figure 2-
10, lane 12). 
  This result demonstrated that 3 or 4 hours were the optimal protein 
delivery time for LBD-apoER2, as during this time the original protein band was  
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hardly detectable (Figure 2-10, lanes 4 and 5), suggesting that it has been taken 
up by the cell. This slower mobility band was replaced by the faster one at 4 hrs 
and thereafter (Figure 2-10 lanes 5-11) suggesting it to be the secreted protein.  
After an additional 12 hours of incuation, the secreted protein could not be 
detected. 
 After protein delivery, the properly refolded LBD-apoER2 should be 
secreted into the medium in the later time point including overnight incubation. 
The LBD-apoER2 only includes the ligand-binding domain of apoER2 with the 
trans-membrane domain removed. Without the transmembrane and cytosolic 
domains of apoER2, this mini-receptor will be secreted into the culture medium. 
We thought that the new lower faint band observed in the later time points was 
the refolded LBD-apoER2.  
 
Figure 2-11: Western-blotting to detect His-tagged LBD-apoER2 during the same 
time course of QQ-delivery of LBD-apoER2.  
An anti his-tag antibody was used. Lanes 1- 11 were the samples from 0 to 10 hours. 
Lane 12, serum-free DMEM medium sample after another 12 hours of incubation. 
Lane 13, the bacterially expressed LBD-apoER2 as a positive control. Lane 14, RAP 
full length without His-tag as a negative control.  
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 To confirm the result of this time course, all the medium samples were 
subjected to Western blotting using an anti His-tag antibody with bacterially 
expressed LBD-apoER2 as a positive control and non-His-tagged RAP as a 
negative control (Figure 2-11). The result showed the same pattern of QQ-
modified LBD-apoER2 in the delivery medium as the SDS-PAGE shown in 
Figure 2-10. At 3 or 4 hours, the density of LBD-apoER2 protein bands was 
sharply decreased and gradually disappeared by 10 hours after protein delivery 
(Figure 2-11, lanes 4-11). However, the secreated LBD-apoER2 in the later time 
points could not be detected by these Western blotting conditions (compare the 
trend of the faster mobility band in Figure 2-10 to Figure 2-11).  This may be due 
to different conformations adopted by the refolded protein, whereby the His tag 
could be buried and inaccessible to the anti His-tag antibody. Our ligand-blotting 
data confirmed this suggestion (see 2.3.3). Up to this point, our data indicate that 
the QQ-modified LBD-apoER2 was efficiently delivered into HeLa cells and that 
the optimal LBD-apoER2 delivery time was 3 or 4 hours. 
 
2.3.3. The LBD-apoER2 reaches to the ER after QQ-protein delivery.  
 Bacterially expressed LBD-apoER2 is misfolded, forming a mixture of 
different oligomers (Figure 2-12, panel A, lane1), which are inactive for ligand-
binding. We designed specific experiments based on the following 
considerations: 1) The refolding process of LBD-apoER2 happens in the ER 
(189). 2) The refolding may occur in two steps: monomer formation and refolding.  
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Figure 2-12: A:  A Western blot of LBD-apoER2 using a 12% SDS-PAGE and an 
anti-His-tag antibody. 
 
Braakman et al previously suggested that the newly synthesized 
endogenous LDLR folded in a coordinated, non-vectorial pathway that included 
non-native disulfide bond formation and reshuffling (189). In our case, once the 
 Lane 1: bacterial expressed LBD-apoER2 without DTT. Lane 2: the refolded LBD-
apoER2 from HeLa cells. Lane 3: bacterial expressed LBD-apoER2 with 20 mM DTT. 
Co-localization experiments: B, fluorescence image of CFP channel (blue). C, 
fluorescence image of rhodamine channel (red). D, fluorescence image of FITC 
channel (green). E, Merge of the fluorescence images from all three channels with 
the light microscopy image (Courtesy of Dr. Qianqian Li).  
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bacterially expressed LBD-apoER2 is delivered into cells, the folding machinery 
has to break up the oligomers to form a monomer for refolding. The correctly 
refolded LBD-apoER2 should traffic from the ER to the Golgi, and eventually 
secrete into the cell culture medium via the plasma membrane. 
We transfected HeLa cells with both CFP-Golgi and GFP-ER marker 
DNAs and incubated the transfected cells for 72 hours before protein delivery. 
The transfected DNA labels the ER with green and the Golgi with blue 
fluorescence (116).  We also labeled LBD-apoER2 with DyLight 649 and 
delivered this red fluorescence labeled protein into the transfected cells. The 
cells were washed and incubated in a regular cell culture medium for another 6 
hours and subjected to fluorescence imaging (Figure 2-12, panel B,C,D,E). 
Clearly, a merge of CFP (Panel B, Golgi location) with FITC (Panel D, ER 
location) and rhodamine channels (Panel C, LBD-apoER2 intracellular location) 
shows merging fluorescence (Panel E), demonstrating that the delivered LBD-
apoER2 is in the ER and Golgi for refolding. 
 
2.3.4.    Optimizing the in vivo protein refolding protocol for LBD-apoER2 
 Our time course data suggested that the bacterially expressed LBD-
apoER2 was efficiently delivered into the HeLa cells. The delivered, bacterially 
expressed LBD-apoER2 should be inside the ER for refolding, which takes time. 
The properly refolded LBD-apoER2 should follow the secretary pathway for 
secretion into the serum-free medium, while the persistent unfolded LBD-apoER2 
would be degraded by the ERAD, since the transmembrane domain of LBD-
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apoER2 was removed. This raised an important question as to when was the 
best time point to re-purify the properly refolded LBD-apoER2 from the cell 
culture medium for the highest yield of refolding.  
 
Figure 2-13: Ligand-blotting assay to detect RAP binding to the functional LBD-
apoER2 after refolding.  
  
 We addressed this question using a ligand-blotting assay with these time 
course samples. Ligand-blotting can be used to specifically detect properly folded 
LBD-apoER2 due to its binding to RAP. While the bacterially expressed LBD-
apoER2 is delivered into HeLa cells, their protein folding machinery will try to 
refold the delivered LBD-apoER2, and the properly refolded protein will be 
secreted from the cells. This is a continuous process. Our ligand-blotting assay 
Three ul of the medium were spotted onto a nitrocellulose membrane. The blot was 
incubated with 20 ug/ml full-length RAP after blocking. The bound RAP was probed 
by rabbit anti-RAP antibody followed by goat anti-rabbit IgG. Lanes 1-11 were the 
time points of 0 to 10 hours. Lane 12, serum-free DMEM medium sample after 
another 12 hours incubation. Lane 13, 0.1 mg/ml bacterial expressed LBD-apoER2 
as a negative control. Lane 14, RAP full-length as a positive control.  
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result (Figure 2-13) showed that the refolded LBD-apoER2 was indeed secreted 
into the medium and gradually accumulated in the medium. At 0-3 hours, nearly 
no positive dot-blot signals were observed (lanes 1-4), which was confirmed by 
the negative control of Lane 13, the bacterially expressed LBD-apoER without in 
vivo refolding. As time proceeded, significant intensity of the dot-blot signals were 
observed at 4-7 hours (lanes 5-8). At 8-hours, the strongest signal was observed 
which was maintained all the way to 10-hours (lanes 9-11). In addition, strong 
dot-blot signals were also observed in the medium of another overnight cell 
culture (lane 12). This data indicated that the cell culture medium during this time 
course contained the secreted and properly refolded LBD-apoER2 and the 
refolded LBD-apoER2 reached the highest concentration at 8-hour after QQ-
delivery. In addition, the amount of the refolded protein was continuously 
accumulated in the cell culture medium during an overnight cell culture with QQ-
protein delivery. 
 Although the refolded LBD-apoER2 could not be detected in the 
Coomassie stained gel after an additional overnight incubation (Figure 2-10 lane 
12), the dot blot clearly demonstrated that the refolded protein was indeed 
present in the overnight medium (Figure 2-13, lane 12).  As the overnight 
medium did not harbor any QQ-modified protein, coupled with the lack of signal 
from the undelivered bacterially expressed protein (Figure 2-13, lane 13), the 
similar trend between the fast mobility band (Figure 2-10, lanes 3-11) and the 
RAP dot blot (Figure 2-13) strongly argue that the faster mobility band observed 
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(Figure 2-10) is likely the functional and refolded LBD-apoER2, being responsible 
for the RAP binding (Figure 2-13). 
 We quantified the ligand-blotting data using the Kodak 1D image analysis 
software. As shown in Figure 2-14, the amount of the refolded LBD-apoER2 kept 
increasing until the 8 hours time point where it reached its peak. After 8 hours, 
the amount of the refolded LBD-apoER2 in the incubation medium remained 
constant. 
 
Figure 2-14: The bar graph of signals quantified from the ligand-blotting assay 
(Figure 2-13), showing the accumulation of the secreted and refolded LBD-apoER2 
in the serum-free medium. 
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 Since this in vivo refolding is a complicated process, containing protein 
refolding, ERAD degradation of consistently misfolded protein, and secretion of 
the folded protein, it is difficult to identify the best timing to obtain the highest 
yield of the refolded protein. However, our data clearly indicated that the 
secretion of the refolded LBD-apoER2 peaked at 8 hours after protein delivery. 
Eight to 10 hours incubation time for in vivo refolding was the optimal condition. 
 
2.3.5.  Refolded LBD-apoER2 was secreted into culture medium. 
For LBD-apoER2 in vivo refolding, our optimal experimental condition 
was 4-hour QQ-protein delivery, followed by an additional 8-10 hours for protein 
refolding and secretion (Figure 2-15). Under this condition, most bacterial 
recombinant LBD-apoER2 was delivered inside HeLa cells by the QQ-protein 
delivery. The delivered LBD-apoER2 was refolded by the ER refolding machinery 
and most refolded LBD-apoER2 was secreted into the cell culture medium. We 
focused on cell culture medium to take advantage of the secreted LBD-apoER2 
since it should be properly refolded and relatively more pure as compared to the 
LBD-apoER2 inside HeLa cells that might contain mixed population of refolded 
and misfolded LBD-apoER2. 
To confirm this, medium samples at different time points were taken 
during protein refolding, and HeLa cells were also lysed afterwards. All samples 
were subjected to a SDS-PAGE with or without DTT. HeLa cells were also 
incubated with the protein delivery medium that only contained QQ-reagent  
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Figure 2-15: 12% SDS-PAGEs, showing the in vivo protein refolding.  
HeLa cells were incubated with the protein delivery medium for 4 hours. The protein 
delivery medium was exchanged to fresh serum-free DMEM medium without QQ-
LBD-apoER2 and cultured for another 10 hours.  The samples were subjected to 
SDS-PAGE analyses without (left) and with (right) DTT. Lane 1, the HeLa cell lysates 
after 4-hour protein delivery and 10-hour protein refolding. Lane 2, the control HeLa 
cell lysates without protein-delivery. Lane 3, the protein delivery medium with 0.1 
mg/ml bacterial expressed LBD-ApoER2 before adding HeLa cells. Lane 4, the 
protein delivery medium after 4 hours post protein delivery. Lane 5, the culture 
medium after 10 hours of protein refolding. Lane 6, the cell culture medium with QQ-
reagent without adding HeLa cells as a negative control. Lane 7, the control HeLa cell 
culture medium with the QQ-reagent only after 4 hour culture. Lane 8, the serum-free 
DMEM medium after another 10 hour with the control HeLa cells. The blue arrow 
head indicates a secretion protein from HeLa cells.  The faint yet properly refolded 
LBD-ApoER2 band that is secreated into the medium is noted by a red arrow.  
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under the same experimental condition. The cell culture medium of this control 
experiment were also taken as a negative control. 
Consistent with our previous data, LBD-apoER2 was not detectable in the 
HeLa cell lysates (lane 1) and was only detectable in the cell culture medium 
(lane 5) (Figure 2-15). This result confirmed the suggestion that protein refolding 
did not lead to the accumulation of the LBD-apoER2 inside HeLa cells. Instead, 
the properly refolded LBD-apoER2 was secreted into the cell culture medium. In 
addition, our data indicated that the QQ-protein delivery method efficiently sent 
the LBD-apoER2 inside HeLa cells since the LBD-apoER2 band intensity was 
significantly decreased (lane 4). Accordingly, Lane 5 showed detectable refolded 
LBD-apoER2 after 10-hour cell culture (red arrow). The higher molecular weight 
bands shown on the gels (lanes 4, 5, 7, and 8, Blue Arrow Head) came from a 
HeLa cell secretary protein, which persistently existed in the medium during in 
vivo protein refolding. This result was confirmed by the negative controls on the 
SDS-PAGE gels (lanes 6-8). 
  
2.3.6.    The yield of refolded LBD-apoER2 
 The incubation medium (serum-free) was collected after refolding and 
the properly refolded LBD-apoER2 was subjected to protein purification using the 
nickel chelating column. Our results showed that the biochemical properties of 
the properly folded LBD-apoER2 were different from the bacterially expressed 
protein. The solubility of the folded LBD-apoER2 was lower and the binding 
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capability to the nickel chelating column was decreased. This is consistent with 
the possibility that the his-tag may be partially occluded in the refolded protein 
and could be responsible for the lack of signal in the Western (Figure 2-11) and 
the decreased binding observed despite the his-tag being present.  This forced 
us to optimize the purification protocol for the refolded LBD-apoER2. Three main 
modifications were carried out: (1) the volume of purification buffer was increased 
to reduce the refolded LBD-apoER2 concentration and to decrease potential 
possibility of precipitation; (2) high concentrations of NaCl in the purification 
buffer were included in order to avoid non-specific protein binding to the His•Bind 
column and to increase the solubility of the refolded LBD-apoER2; (3) decreased 
concentrations of imidazole in the elution buffer because we found that high 
concentrations of imidazole would cause irreversible aggregation and 
precipitation of the refolded LBD-apoER2 during dialysis. The lower 
concentration of imidazole was sufficient to elute the refolded protein due to the 
weaker interaction with the column resin.  
 Even though we optimized protein delivery, protein refolding, and protein 
purification conditions throughout this in vivo protein refolding technique for LBD-
apoER2, the final yield of the purified refolded LBD-apoER2 remained low. We 
obtained a yield less than 10% of the refolded LBD-apoER2 compared to the 
imput amount (QQ modified, bacterially expressed protein used for delivery) as 
shown in Table 2-1.  
 This is not surprising since LBD-apoER2 contain 21 disulfide bonds and 
7 Ca2+-binding sites. The folding of this protein is challenging. It has been 
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demonstrated by others that only 30% of the newly synthesized LDLR was 
properly folded and the rest proteins were degraded by ERAD due to misfolding 
(189). Our data confirmed this result for our refolding, since we could only 
recover less than 10% of the bacterially expressed LBD-apoER2 (Table 2-1). 
This suggested that most of the QQ-delivered LBD-apoER2 was degraded due to 
the limits of the ER folding capability. We re-purified the bacterially expressed 
LBD-apoER2 from the protein delivery medium after 4 hours of delivery.  The re-
purified bacterially expressed LBD-apoER2 protein could be re-used in the next 
round of in vivo protein refolding experiments to increase the refolding efficiency. 
Those consistently misfolded LBD-apoER2 were subjected to ERAD degradation 
due to ER quality control system. Another possible reason for this low yield was 
the purification due to the reduced affinity of the refolded LBD-apoER2 for the 
His-tag resin. After refolding, LBD-apoER2 underwent conformation changes that 
might make the his-tag buried and not available to bind to his-tag resin, causing a 
low yield of the refolded LBD-apoER2.  
Table 2-1: Three representative yields of refolded LBD-apoER2. 
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2.3.7.    The refolded LBD-apoER2 is biologically functional 
 To further confirm the purified refolded LBD-apoER2 powder is properly 
folded and biologically functional, we dissolved the protein powder in PBS buffer 
with 1 mM CaCl2 and performed Western blot and ligand blotting. As shown in  
Figure 2-16 A-C, with (lanes 3 and 4) or without reducing reagent DTT (lanes 1 
and 2), the refolded LBD-apoER2 (lanes 1 and 3) showed the same mobility as 
the bacterially expressed one (lanes 2 and 4) on the 12% SDS-PAGE gel (Panel 
A). Western blotting (Panel B and C) showed positive signals for the refolded 
LBD-apoER2 as well as the bacterially expressed one, identifying the protein 
powder was LBD-apoER2. Interestingly, the LBD-ApoER2 antibody only 
recognized the protein when it was under reducing conditions (panel B, lanes 3 
and 4) suggesting that the epitope is hidden in the refolded (lane 1) or misfolded 
proteins (lane 2).  However, the His tag remained accessible as its was detected 
in all lanes (panel C).  Likely, the properly refolded LBD-ApoER2 was not 
detected in Figure 2-11 due to its trace amount but was clearly detected here 
(Figure 2-16, panel C).  Ligand-blotting assay (panel D) of the refolded LBD-
apoER2 protein powder showed a positive signal, similar to the RAP dot-blot as 
the positive control. However, the bacterially expressed LBD-apoER2 protein 
powder showed a negative signal. This result confirmed that the refolded LBD-
ApoER2 powder displayed a proper conformation that bound to RAP. Thus, the 
refolded LBD-apoER2 protein powder is biologically functional unlike the 
bacterially expressed one. 
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Figure 2-16: SDS-PAGE, Western blots using anti-apoER2 and anti his-tag 
antibodies and ligand blotting of the refolded LBD-apoER2 protein powder.   
 
 
 
Panel A: a 12% SDS-PAGE stained with Coomassie blue. Panel B: A Western blot 
using anti-apoER2 antibody. Panel C: A Western blot using anti His tag antibody. In 
all three panels, Lane 1, the refolded LBD-apoER2 powder. Lane 2, bacterial LBD-
apoER2 powder. Lane 3, bacterial LBD-apoER2 powder with 10 mM DTT. Lane 4, 
the refolded LBD-apoER2 powder with 10 mM DTT. Panel D: Ligand-blotting to 
detect the binding of RAP to the functional LBD-apoER2. The bound RAP was 
probed by anti-RAP antibody.  
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2.4. Discussion  
 Proteins have to adopt the correct three-dimensional structures in order 
to be functional. Obtaining the native fold of a protein sometimes is not a simple 
task, especially when the protein is expressed in E. coli to meet the need of large 
quantity of properly folded proteins for structural study or for therapeutics. Many 
proteins precipitate in the form of inclusion bodies when synthesized in E. coli. In 
vitro experimental approaches have been developed to refold the aggregated 
proteins into their biologically active forms. The main refolding strategies are 
chromatographic methods and refolding in free solution. New techniques 
employing additives that aid in protein refolding, such as chaperone proteins, 
may become more widely used. However, these new methods require rigorous 
testing for refolding of not only simple model proteins such as RNase A, but also 
for proteins with complex folding.  New techniques of protein refolding are 
needed to increase the robustness of refolding processes and to decrease the 
costs for broader applications.  
 Our lab recently developed a novel in vivo protein refolding technique. 
Different from other in vitro protein refolding techniques, this protein refolding 
technique enables protein refolding inside of mammalian cells and is facilitated 
by folding chaperones and enzymes in the ER and the Golgi. The ER quality 
control system ensures that only properly refolded proteins continue intracellular 
trafficking whereas the persistent unfolded protein is degraded by ERAD or UPR 
(Figure 1-2 and 1-3). Properly folded and biologically functional proteins follow 
the same intracellular trafficking pathway as endogenous ones. Additionally, the 
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refolded protein can be purified from mammalian cells or the culture medium 
depending on the design and properties of the refolded proteins.  
 This in vivo protein refolding technique is based on a highly efficient 
recombinant protein expression method in E. coli and the QQ-protein delivery 
technique, which were recently developed in our lab. Specially, the unique QQ- 
reagent can non-covalently attach to the bacterially expressed proteins, protect 
the proteins from degradation, and efficiently deliver them inside of mammalian 
cells. The delivered proteins traffic to the ER and Golgi and undergo efficiently 
protein refolding by the ER folding machinery. Thus, this in vivo protein refolding 
technique utilizes ER protein folding machinery and quality control system to 
efficiently refold proteins and to ensure that the misfolded proteins will be 
degraded, thus, providing a novel protein refolding technique that is currently 
unavailable for the scientific community. 
 ApoER2 is one of the primary members of LDL receptor family, playing 
an important role in lipid metabolism in the brain and neurodegenerative 
diseases such as Alzheimer’s disease. Like its homologue - LDL receptor, 
apoER2 has five major motifs: complement-like binding repeats/the LDL receptor 
type-A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats, a 
transmembrane domain and a short cytoplasmic tail (Figure 2-1). Studies 
showed that the seven complement-like repeats form a ligand-binding domain, 
mainly responsible for binding to the ligands such as apoE, RAP and Reelin 
(161, 174, 190). Even though no structural information of apoER2 has been 
reported, structure studies on other LDL receptor family members like LDL 
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receptor and LRPs have shown that the each ligand binding repeat in the ligand-
binding domain contains six cysteines, forming three disulfide bonds per repeat 
(190). The negatively charged amino acids (Asp/Glu) at the C-terminus of each 
repeats are considered to be important for the ligand binding function, partially 
complementary to the positively charged residues on apoE or RAP (190). Also, 
these acidic residues form an important calcium coordination site, which is highly 
conserved. Calcium was reported to be important for receptor folding, stabilizing 
the secondary structure and ligand binding (191). Thus, the ligand-binding 
domain of LDLR family has a complex folding and refolding of this complex 
structure is very challenging.  
 We undertook this challenge and explored efficient refolding of the 
human LBD-apoER2 using this in vivo protein refolding technology. We believe 
that this is one of the ultimate measures for this in vivo protein refolding 
technology and the successful refolding of LBD-apoER2 will be a good testimony 
of the enabling capability of this technology. We subcloned the ligand-binding 
domain of apoER2  (LBD-apoER2) into a high-level expression vector which was 
expressed in E. coli using our high cell-density expression method to produce 
gram quantity pure recombinant LBD-apoER2 (59). We then optimized the in vivo 
protein refolding conditions specific for the efficient refolding of LBD-apoER2. We 
showed that QQ-modified bacterially expressed LBD-apoER2 could be efficiently 
delivered inside HeLa cells in 3 to 4 hours at 0.1 mg/ml concentration (Figures 2-
10). Once the delivered LBD-apoER2 reaches the ER (Figure 2-12), the protein 
folding process begins. The bacterially expressed LBD-apoER2 undergoes 
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protein refolding process, which is facilitated by chaperones and folding enzymes 
in the ER. The quality of refolded protein is monitored by the QC system in the 
ER. Persistent unfolded LBD-apoER2 is degraded by ERAD or UPR. The 
properly folded LBD-apoER2 follows the same secretary pathway as 
endogenous counterpart and is secreted into the cell culture medium if it is a 
secretion protein.  
 Because LBD-apoER2 only includes the ligand-binding domain with the 
transmembrane and cytosolic domains removed, this mini-receptor will not locate 
on the cell membrane as the full-length apoER2. Instead, LBD-apoER2 will be 
secreted into the culture medium once they are properly refolded. Our data of a 
time course of refolding indicated that the refolded LBD-apoER2 was gradually 
accumulated in the culture medium with the peak of accumulation at 8-10-hours 
after protein delivery. After reaching the peak, the level of the refolded LBD-
ApoER2 in the medium remained the same during this 10-hour time course. 
Thus, our data suggested that the refolding of the QQ-delivered LBD-apoER2 
might be nearly completed by the ER folding machinery under our experimental 
condition. This allowed us to optimize the in vivo protein refolding protocol for 
LBD-apoER2 by QQ-protein delivery for 4-hours, followed by additional 8-10-
hours of protein refolding in the regular cell culture medium for the best yield of 
the refolded LBD-apoER2. 
 Purification of the refolded LBD-apoER2 from the cell culture medium 
turned out to be a challenging task since the refolded LBD-apoER2 seemed to 
significantly reduce its binding capability to His-tag resin, thus causing a major 
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trouble to purify them. However, this is one of the key steps for the final yield of 
the refolded LBD-apoER2 protein. We had to optimize our standard purification 
protocol by increasing the sample loading volume and NaCl concentration in the 
loading and washing medium and reducing the imidazole concentration in the 
elution buffer. These modifications greatly improved binding capability of the 
refolded LBD-apoER2 to His tag resin that significantly enhanced the purity and 
yield of the refolded LBD-apoER2.  
 We probed the function of the refolded LBD-apoER2 by a ligand-blotting 
assay using RAP as the ligand and an anti-RAP antibody. RAP acts as a 
specialized chaperone inside the ER and binds to properly folded and functional 
ligand-binding domains of the LDLR family including apoER2 with nM binding 
affinity (174). No denaturing reagents or detergents were used in this ligand-
blotting assay. However, 1 mM calcium ion was added since calcium was critical 
for RAP-binding to LBD-apoER2. The pH was adjusted to 7.2 to mimic the pH 
inside the ER. Our data clearly demonstrated that the properly refolded LBD-
ApoER2 was biologically active for RAP binding, confirming the efficiency of this 
novel in vivo protein refolding technology.  
 This in vivo protein refolding technique is unique compared to the other 
in vitro protein refolding techniques. It takes advantage of the efficiency of the ER 
folding machinery of mammalian cells. By providing a physiological environment, 
the bacterially expressed misfolded LBD-apoER2 was efficiently refolded by the 
ER folding chaperones and enzymes. In addition, the refolding quality of LBD-
apoER2 is closely monitored by the quality control system in the ER. Only the 
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properly refolded protein can be further subjected to post-translational 
modifications and eventually secreted into cell culture medium. In contrast, the 
persistent unfolded LBD-apoER2 is degraded by ER-associated degradation or 
unfolded protein response mechanism in the ER.  
 This was confirmed by the previous data of my colleague Dr. Qianqian Li, 
who delivered the bacterially expressed MESD inside mammalian cells (data not 
shown). After purification, she found two major glycosylation forms of MESD in 
addition to the native MESD protein. The glycosylation patterns were the same 
as those of the endogenous MESD. This is an important achievement since 
properly posttranslationally modified and refolded proteins are important to the 
biological activity of a protein, which is especially critical towards the production 
of therapeutic proteins for human disease therapies. Our results suggest that we 
have successfully achieved this goal for refolding of LBD-apoER2. 
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Chapter III 
Refolding of the beta-propeller/epidermal growth factor-like (EGF) domain I 
of low-density lipoprotein (LDL) receptor-related protein 6 (BP1-LRP6) 
inside of mammalian cells 
 
3.1.   Introduction 
3.1.1. LRP5/6 are members of the low-density lipoprotein receptor (LDLR) 
family with unique structural arrangements 
The LDLR family contains more than 14 members of cell surface 
receptors. Although the members in this family performs diverse functions, they 
share common structural domains: 1) ligand-binding domain of the complement-
type (CR)repeats, 2) epidermal growth factor (EGF) -like repeats, 3) YWTD 
(Tyr−Trp−Thr−Asp) β-propeller domains, 4) a transmembrane domain, and 5) 
one or more endocytic motifs within their cytoplasmic domains (Figure 2-1) (192). 
LDL receptor-related protein 5 (LRP5) and LRP6 are structurally diverse from the 
other LDLR family members. Rather than having large clusters of ligand binding 
CR repeats in the extracellular region, LRP5/6 contain only three ligand binding 
CR repeats that are next to the transmembrane region (Figure 2-1). Instead, the 
YWTD β-propeller/EGF (BP) modules occupy most of the extracellular domain 
and play important functional roles. Ligands of other LDLR members typically 
bind to clusters of ligand-binding CR repeats, whereas all identified ligands for 
LRP5/6 bind to the YWTD β-propeller/EGF (BP) modules (192). Evidence 
implicating YWTD domains in protein−protein interactions has emerged from 
several studies. LRP6 from xenopus along with its homologs in mice and the fly 
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(Drosophila) binds to the developmental signaling protein Wnt, implicated as a 
co-receptor in Wnt signaling (141-143). 
The LDLR family members play important roles in diverse physiologic 
progresses, including lipoprotein metabolism, protease regulation, calcium 
homeostasis, cell migration, and embryonic development (193). For example, 
VLDLR and ApoER2 mediate Reelin signaling in neuronal cell migration during 
embryonic development (140), and LRP1 participates in PDGF-mediated 
signaling (194). However, LRP5 and 6 were identified as indispensible co-
receptors of the canonical Wnt/β-caternin pathway and function primarily in Wnt 
signaling pathway (141, 142).  
 
3.1.2. LRP5/6 are essential receptors for the canonical Wnt signaling 
pathway 
The discovery of the common evolutionary origin of the Drosophila 
segment polarity gene Wingless and the murine proto-oncogene Int-1 laid the 
foundation for the canonical Wnt signaling pathway (195). The name Wnt was 
coined as a combination of Wg (Wingless) and Int. The Wnt signaling pathway 
plays a critical role in orchestrating proper tissue development in embryos and 
tissue maintenance in adults (196-198). It has been shown that Wnt activates at 
least three intracellular signaling pathways including the Wnt/β-catenin (canonical 
Wnt pathway), planar cell polarity (PCP), and Ca2+pathway (Figure 3-1) (199). In 
the PCP pathway, Wnt activates small G protein including Rho and Rac through 
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Dishevelled (Dsh), thereby activating Rho-associated kinase (ROCK) and JNK 
(200). The PCP pathway is involved in the regulation of tissue polarity, cell 
migration, and cytoskeletal arrangement. Furthermore, Wnt increases the 
intracellular Ca2+ concentration probably by activating protein kinase C (PKC) 
and Ca2+/calmodulin-dependent protein kinase. The Wnt/Ca2+ pathway regulates 
cell adhesion and cell movement during gastrulation (201).  
The canonical Wnt pathway, which regulates the ability of the β-catenin 
protein to drive activation of specific target genes, is better characterized. In the 
absence of a Wnt signal, β-catenin is actively degraded in the cell by the actions 
of a multiple-protein complex called the “destruction complex”. Within the 
complex the Axin and adenomatous polyposis coli (APC) form a scaffold that 
facilitates β-catenin phosphorylation by casein-kinase I α (CK1 α) and glycogen 
synthase kinase (GSK3 β). The phosphorylated β-catenin is subsequently 
recognized and ubiquitinylated, resulting in its proteasomal degradation (Figure 
3-2) (202). However, in the presence of Wnt signals, β-catenin can be 
accumulated and be translocated to the nucleus, where it interacts with the T-cell 
factor/lymphoid enhancing factor (TCF/LEF) family of transcription factors, 
leading to the transcription of Wnt target genes (202). The Wnt/ β-catenin 
signaling pathway directs a specific set of genes that strictly control temporal and 
special regulation of cell proliferation, differentiation, survival, and movements 
(197, 198). Therefore, aberrant activation of this pathway can lead to tumor 
formation. 
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Figure 3-1: A schematic representation of the Wnt signal transduction cascade 
(199).   
 
 
(b) For non-canonical or planar cell polarity (PCP) signaling, Wnt signaling is 
transduced through Frizzled independent of LPR5/6. Utilizing the PDZ and DEP 
domains of Dsh, this pathway mediates cytoskeletal changes through activation of the 
small GTPases Rho and Rac. (c) For the Wnt-Ca2+ pathway, Wnt signaling via 
Frizzled mediates activation of heterotrimeric G-proteins, which engage Dsh, 
phospholipase C (PLC; not shown), calcium-calmodulin kinase 2 (CamK2), and 
protein kinase C (PKC). This pathway also uses the PDZ and DEP domains of Dsh to 
modulate cell adhesion and motility. Note that for the PCP and Ca2+ pathways Dsh is 
proposed to function at the membrane, whereas for canonical signaling Dsh has been 
proposed to function in the cytoplasm  
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LRP5 and LRP6 exhibit overlapping, as well as distinct, tissue- and cell-
type-specific expression patterns (192, 203). Mice deficient in Lrp6 gene are 
embryonic lethal; the mutant embryos exhibit developmental defects that 
resemble the phenotypes observed for individual Wnt ligand mutants, including 
mid/hindbrain defects, posterior truncation, and abnormal limb patterning (141). 
In contrast, LRP5 knock out (KO) mice are viable and fertile, although they 
exhibit low bone mass and eye vascularization defects (152). Interestingly, it has 
been shown that overexpression of LRP6 confers significantly stronger Wnt 
signaling activity than LRP5 in Xenopus and mammalian cells (142, 192). Thus, it 
is possible that LRP5 and LRP6 exhibit functional redundancy, most likely by 
acting with different efficiencies in a context-dependent manner. The features of 
LRP5-KO mice recapitulate human osteoporosis-pseudoglioma syndrome, 
whereas gain-of-function mutations in Lrp5 affects the homeostatic balance of 
osteoblasts and osteoclasts after birth, which leads to high bone mass (152, 
204). Recently, LRP6 mutations and polymorphisms were found to be associated 
with various human diseases, including coronary artery disease, Alzheimer’s 
disease, hyperlipidemia, and osteoporosis (192, 205). These studies indicate a 
possible predominant role of LRP5 in bone development and maintenance and a 
broader role of LRP6 in pathophysiology. 
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Figure 3-2: A simplified classical view of Wnt/β-catenin signaling (192).  
 
(A) Without Wnt, the scaffolding protein Axin assembles a protein complex that 
contains Apc, Gsk3, Ck1, and β-catenin. In this complex, β-catenin is sequentially 
phosphorylated by Ck1 and Gsk3. Phosphorylated β-catenin is recognized by β-Trcp, 
which is a component of an ubiquitin-ligase complex that conjugates β-catenin with 
ubiquitin. Poly-ubiquitinated β-catenin is degraded by the proteosome. TCF/LEF-
associated co-repressors, such as Groucho, and Axin-associated Diversin, PP2A and 
other proteins are omitted for simplicity. (B) In the presence of Wnt, β-catenin 
phosphorylation and degradation is inhibited. Accumulated β-catenin forms a nuclear 
complex with the DNA-bound TCF/LEF transcription factor, and together they activate 
Wnt-responsive genes. This signaling cascade is perhaps initiated by a Wnt-induced 
Fz-Lrp5/Lrp6 co-receptor complex, which recruits Axin to the plasma membrane 
through Lrp5/Lrp6-Axin association. Fz-associated Dishevelled (Dvl) protein may bind 
Axin and inhibit Axin-Gsk3 phosphorylation of β-catenin, either directly or indirectly  
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3.1.3. The YWTD β-propeller/EGF (BP) domain of LDL receptors and the 
molecular chaperone MESD 
 The number and arrangement of different LDLR domains varies greatly 
among different members of LDLR family; in humans, sizes range 5-fold from the 
smallest LDLR (95 kDa) to the largest LRP2 (522 kDa) (206, 207). Such large 
and complex proteins challenge structural studies. However, a crystal structure of 
LDL receptor YWTD β-propeller/EGF (BP) domain was solved as shown in 
Figure 3-3. 
The YWTD repeat is folded into a six-bladed β-propeller domain. Each β-
propeller consists of  six blades arranged radially about a central axis (Figure 3-
3). Along this axis is a central channel, 8−9 Å in diameter, filled with water 
molecules that form hydrogen bonds with backbone and side chain from the β-
strands lining the channel. Each blade of the propeller has four antiparallel β-
strands that are offset from the YWTD repeats.  The “first” strand of the sixth 
blade is a C-terminal strand that follows the fifth blade to complete circularization 
via Dvl-associated proteins. Lrp5/Lrp6-Axin binding may also promote Axin 
degradation. Either or both of these events can lead to β-catenin accumulation. This 
description represents one of several possibilities. The composition of the Axin 
complex upon Wnt stimulation is not well defined. Gsk3-binding protein (GBP/Frat), 
and nuclear β-catenin-associated Legless/Bcl9 and Pygopus are omitted for 
simplicity.  
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of the steroidal YWTD β propeller domain. The YWTD β propeller is followed by 
an EGF-like domain (E3) that packs against the propeller to create a continuous 
hydrophobic core in the mature protein (130). The linker connecting the propeller 
to E3 packs tightly against the base of the propeller and contacts predominantly 
hydrophobic side chains in the 1−2 loops of blades two and three, situating E3 in 
contact with the second and third blades of the propeller. The large interface area 
between the YWTD domain and the C-terminal EGF modulesuggest that other 
members of the LDLR family will share this organization, including the BP 
domain of LRP-6.  
 
Figure 3-3: Ribbon representation of the YWTD domain and adjacent C-
terminal EGF-like module (E3) of the LDL receptor, colored to point out the 
six YWTD repeats of the six-bladed propeller (130).  
 
For LDLR and LRPs, at least two private chaperones, the LRP-receptor-
associated protein (RAP) and the Boca/Mesd chaperone, are dedicated to the 
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folding and maturation of these multi-domain proteins as they transit through the 
secreatory pathway to the cell surface (114, 115). RAP binds the cysteine-rich 
ligand-binding modules of LDLR family members, preventing premature 
association with their respective ligands. Also, RAP escorts fully folded LDLR 
family members from the ER to the Golgi, where the lower pH triggers RAP to 
dissociate and recycle back to the ER via its retention signal (126). In Drosophila, 
Boca was shown to promote maturation and surface expression of several LDLR 
family members through a direct, but transient, interaction (114, 187). Boca/Mesd 
family members are localized in the ER, where they aid in the folding of YWTD β-
propeller domains. ER chaperone proteins provide the most prevalent 
mechanism for achieving quality control during protein translation and 
translocation (208). Boca/MESD are important for the folding of LRP5 and LRP6,. 
Our lab recently solved the high resolution NMR structure of full-length of 
MESD (209).  MESD contains two structural and functional domains: a 
chaperone domain and an escort domain. The chaperone domain is located in 
residues 1-150 and highly structured, with a four-stranded anti-parallel β-sheet in 
the center, surrounded by two rigid helices on the top and one rigid helix in the 
bottom. Another flexible short helix is also above the sheet, containing several 
critical binding-residues to the BP domain of LRP6. The escort domain is located 
in residues 151-195 and is flexible, containing two short helices and an array of 
conserved lysine and arginine residues.  
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3.1.4. Challenge of refolding of BP1-LRP6 
The BP1-LRP6 is a 328-amino acid  fragment at the N-terminal of LRP6, 
including six YWTD β-propeller motifs and one epidermal growth factor (EGF)-
like repeat. It is a  multiple domains protein with three disulfide bonds in the EGF 
domain. Refolding such a complex multiple-domain protein BP1-LRP6 in vitro is  
challenging. Spontaneous refolding in vitro is only efficient for small, single-
domain proteins that fold rapidly. multiple domain proteins often refold 
inefficiently due to the formation of partially folded intermediates that tend to self-
associate (aggregate) into disordered complexes, driven by hydrophobic forces 
and inter-chain hydrogen bonding. The aggregation process irreversibly removes 
proteins from their productive folding pathways and only can be avoided in vivo 
protein refolding facilitated by molecular chaperones.  
Previous in vitro protein folding studies with BP1-LRP6 have shown that 
not only the formation of disulfide bonds in vitro occurs significantly slower than 
in vivo, but also the efficiency of forming native disulfide bonds in vitro is 
dramatically lower than in vivo, even under the most favorable condition (210). 
During in vitro refolding, non-native disulfide bonds may be formed. Compared 
with the lower efficiency of forming native disulfide bonds in vitro, our in vivo 
protein refolding technique can offer much greater native disulfide bond formation 
efficiency. 
Specific ER chaperone MESD was reported to be necessary for the 
folding of BP1-LRP6 (211). Our in vivo protein refolding technique can equip the 
refolding process with complete molecular chaperones and folding enzymes, 
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greatly increasing the refolding efficiency.  Therefore, to refold large quantities of 
bacterially expressed BP1-LRP6 into its native conformation, we used our novel 
in vivo protein folding technology.  
 
3.2. Material and methods 
3.2.1. Strain, plasmid and media 
E. coli cells were grown in Luria-Bertani (LB) medium (BD) at 37℃ and 
then were grown in minimal M9 medium at 20℃ for overnight. Kanamycin (30 
µg/ml) was added as required. E. coli stain ER2556 [genotype: F − λ − fhuA2 [lon] 
ompT lacZ::T7 geneI gal sulA11 ∆(mcrC-mrr)11::IS10 R(mcr-73::miniTn10)2 
R(zgb-210::Tn10) 1 (TetS) endA1 [dcm]; New England Biolabs] was used for 
molecular cloning. E. coli strain BL21(DE3) [F- ompT hsdSB (rB-mB-) gal dcm 
(DE3 [lacI lacUV5-T7 gene1 ind1 Sam7 nin5; New England Biolabs] was used for 
protein expression and purification. BP1-LRP6 with an N-terminal 6-histidine tag 
was expressed from plasmid pET30a (+) (Novagen). 
 
3.2.2. DNA manipulation 
The original long his-tag of the pET30a (+) vector (Novagen) was replaced 
by a short His tag containing six histidine plus two serine residues by 
mutagenesis. Mutagenesis was carried out using the QuickChangeTM site-
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directed mutagenesis kit (Stratagene, CA). The mutations were confirmed by 
DNA sequencing.  
Human BP1-LRP6 cDNA (kindly provided by Dr. Guojun Bu, Mayo Clinic, 
Jacksonville, FL, USA) was used as the template of PCR. BP1-LRP6 was 
constructed by subcloning PCR products into the BamHI/XbaI sites of the 
engineered pET30a(+) vector. BP1-BP1-LRP6 includes six YWTD β-propellers 
and one EGF repeat, referring the residues 20-324 of full-length LRP6. The 
constructs derived from PCR were confirmed by DNA sequencing.  
The engineered pET30a (+) vector  provide high protein expression level. 
The confirmed positive DNA constructs were first transformed into the E. coli 
strain ER2566 competent cells for plasmid DNA replication and glycerol stock 
production. Ultimately, they were transformed into BL21 (DE3) cells for protein 
expression. 
 
3.2.3.  Protein expression and purification  
Protein expression was carried out using the E. coli strain BL21(DE3). A 
10-15 ml overnight culture in a rich medium, such as 2×YT, was made from a 
glycerol stock of BP1-LRP6 expressing cells. The next morning, the overnight 
culture was diluted into the LB medium with a ratio 1:100. The culture was grown 
in LB medium with 30 ug/ml kanamycin at 37 °C until it reached an OD600 of 0.8-
1.0. The cells were spun down and re-inoculated into a minimal M9 medium 
(kanamycin, 30 µg/ml) at half volume of LB medium. The culture was continued 
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at 20 °C for one hour. A sample of the culture was take n to check its OD600 to 
confirm the continuous growth of cells under lower temperature and the minimal 
M9 medium. Then expression of the recombinant BP1-LRP6 was induced by 
IPTG at the concentration of 1 mM for overnight at 20 °C. The cells were 
harvested by centrifuge the next morning. The cell pellet was resuspended in 
binding buffer (10 g/ml cells, 20 mM Tris-HCl, 500 mM NaCl, 2.5 mM imidazole, 6 
M urea at pH 8.0) of His tag affinity purification system followed by sonication 
while on ice. To separate the cell pellet from the supernatant, the cell pellet was 
spun down. The pellet was again resuspended in the binding buffer containing 6 
M urea and then sonicated on ice again. This procedure was repeated three 
times to ensure complete solubilization of all bacterially expressed BP1-LRP6 in 
the inclusion bodies in this buffer system. All supernatant fractions were 
combined and applied on a HisBind® resin column (Novagen). The column was 
extensively washed with binding buffer containing 6 M urea followed by washing 
with 100-500 ml of wash buffer harboring 20-30 mM imidazole. The purified 
recombinant BP1-LRP6 was eluted from the column using elution buffer with 1.0 
M imidazole and 6 M urea. The eluted protein was dialyzed against 10 mM 
ammonium bicarbonate to remove the unwanted salt and imidazole in the buffer . 
Ultimately, the dialyzed protein solution was lyophilized to get the pure BP1-
LRP6 protein powder. The protein powder was weighed and was stored at -20 °C 
for future experimental purposes. 
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3.2.4. Time course for QQ-protein delivery  
 The bacterially expressed BP1-LRP6 was modified with QQ-reagent 
overnight at 4 °C with gently shaking. Modified BP1-L RP6 was centrifuged at 
5000 rpm for 5 minutes to remove precipitation. Then the modified BP1-BP1-
LRP6was mixed with serum-free DMEM to reach a final protein concentration of 
0.1 mg/ml. Eighteen dishes (35 cm2) of 80% confluent (about 0.3×106 cells) HeLa 
cells were incubated with the protein delivery medium and protease inhibitor for 3 
hours. Another 3 dishes of HeLa cells were incubated with QQ-reagent only (no 
BP1-LRP6) for 3 hours as a negative control. Samples of HeLa cells were taken 
in triplicate every 30 minutes to monitor the protein delivery efficiency. All the 
samples were subjected for SDS-PAGE gel electrophoresis with or without DTT. 
 
3.2.5. Confocal fluorescence imaging 
 Zeiss Apotome microscopy system is useful for optical sectioning in 
multicolor applications and for high-resolution fluorescence microscopy. We use 
this system to monitor and visualize the protein delivery of fluorophore attached 
BP1-LRP6.  The bacterially expressed BP1-LRP6 was first dissolved in PBS 
buffer, pH 7.4 (0.5-1.0 mg/ml), overnight. The solution then was spun for 10 
minutes at 12,000xg at room temperature. Seventy ul of protein solution was 
taken and 1 µl of amine-reactive ArrayIt®Green540 was added at room 
temperature. Incubation was carried out for 6 hours or overnight in a cold room 
and then purified using a desalting spin-column at 10,000 rpm for 4 minutes to 
remove free dye. The purified, fluorescence labeled protein was incubated with 
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QQ-reagent overnight without further purification. HeLa cells were seeded three 
days before the experiment to reach 80% confluency. QQ-reagent modified, 
fluorophore labeled BP1-LRP6 in serum-free DMEM culture medium was 
incubated with Hela cells at 37 °C for 1 hour or 2 hours. The cells were very 
healthy after protein delivery, displaying normal morphology (Figure 3-7). Cells 
were washed with PBS extensively to remove any labeled protein from the 
medium. Then the Hela cells were subjected to confocal fluorescenceimaging 
using a Zeiss Axioplan2 Imaging fluorescent microscope with ApoTome imaging 
at the Microscopy and Imaging Resources Laboratory at Wayne State University, 
School of Medicine. Fluorescence was recorded with an AxioCam MRm camera 
and AxioVision software. 
 
3.2.6.  Far-Western blot 
           The cell lysates on a native PAGE gel were tansferred onto a 
nitrocellulose membrane at 380 mA for 2 hours. After transfer, the membrane 
was incubated at room temperature with the probe---MESD, which is the private 
chaperone of LRP5/6 and can specifically bind to the properly folded BP1-LRP6. 
The membrane was then washed three times with 20 ml PBS for 5 minutes each 
time, to remove unbound MESD. The membrane was incubated with anti-MESD 
(Abnova) for 1 hour in 2% dry milk PBS, followed by incubation with HPR-
conjugated seconday antibody for 1 hour. At last, the membrane was detected 
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using ECL (Pierce). Using this assay, properly folded BP1-LRP6 can be detected 
because of the formation of the MESD/BP1-LRP6 complex. 
 
3.2.7. Time course for protein refolding  
 Protein refolding inside mammalian cells takes time, especially for BP1-
LRP6. We delivered large quantities of bacterially expressed BP1-LRP6 inside 
HeLa cells. After protein delivery, we set up a three-day protein refolding time 
course experiment to monitor the refolding and stability of the delivered BP1-
LRP6 inside HeLa cells. 
 BP1-LRP6 first was modified with QQ-reagent for overnight at 4 °C. Then 
QQ-reagent modified BP1-LRP6 was mixed with serum-free DMEM to reach 0.1 
mg/ml concentration. The protein delivery medium was incubated with 80% 
confluent HeLa cells for 3 hours (the optimal protein delivery condition) at 37 °C. 
Then the protein delivery medium was removed and the Hela cells were gently 
washed with pre-warmed PBS buffer three times. Hela cell samples were taken 
in triplicate to monitor the protein delivery. During the three-day protein refolding 
time course experiment, Hela cells were incubated with fresh serum-free DMEM 
and every 24 hours, HeLa cell samples were taken to monitor the protein folding 
and the protein stability inside of the cells. One flask of cells was set aside, only 
loading with QQ-reagent protein delivery medium (without BP1-LRP6) as a 
negative control. 
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3.2.8. Detection of the refolded BP1-LRP6 by Western blot 
 The recombinant BP1-LRP6 was fused with His-tag. Protein purification 
was performed using nickel chelating resin column. The purified refolded BP1-
LRP6 protein powder and the bacterially expressed BP1-LRP6 protein powder 
was dissolved in PBS buffer and the concentrations of both of the proteins were 
adjusted to 0.25 mg/ml, confirmed by a BCA protein assay (Pierce). Protein 
samples were loaded at different volumes and analyzed by SDS-PAGE with or 
without the reducing reagent, DTT. Following transferring to PVDF membrane, 
successive incubation with mouse anti-His tag monoclonal antibody (Sigma) or 
mouse anti-BP1-LRP6 antibody (kindly provided by Dr. Jian-Ping Jin) and 
horseradish peroxidase-conjugated secondary antibodies (Amersham Life 
Science) were carried out according to the routine Western blotting procedures. 
The immunoreactive proteins were then detected using the ECL system. 
 
3.2.9. Far UV Circular Dichroism (CD) Spectroscopy 
Circular dichroism (CD) spectroscopy measures differences in the 
absorption of left and right circularly polarized light, which arise due to structural 
asymmetry. Protein secondary structure can be determined by CD spectroscopy 
in the far UV region (190-260 nm). Three common secondary structure motifs (α-
helix, β-sheet, and random coil) exhibit the characteristic and distinctive CD 
spectra in the far UV region. α-Helical proteins have negative bands at 222 nm 
and 208 nm and a positive band at 193 nm. Proteins with well-defined antiparallel 
β-pleated sheets have negative bands at 218 nm and positive bands at 195 nm, 
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whereas disordered proteins have very low ellipicity above 210 nm and negative 
bands near 195 nm.  
CD is reported in units of ellipticity (θ), usually expressed in millidegrees, 
which reflects the sum of the entire molecular population in a sample solution. It 
can be normalized to the molar concentration of the sample as molar ellipticity. 
Circular dichroism spectroscopy is commonly used to: 1) determine if a 
protein is folded; 2) characterize protein secondary structure and tertiary 
structure (using near-UV CD spectrum); 3) compare the structures of a wild-type 
protein with different mutants; 4) study protein stability to temperature or 
chemical denaturation (GdnHCl or urea) and effects of salt, pH, organic solvents; 
5) study protein folding, unfolding, denaturation or aggregation; and 6) determine 
whether protein-lipid interactions alter the conformation of a protein. 
In our studies, CD measurements were carried out on an Olis DSM 17 CD 
spectrophotometer (Bogart, GA), with a constant 20 °C temperature capability 
under computer control within ±0.2 oC. Protein concentrations were determined 
by the BCA protein assay (Pierce) and absorbance at 280 nm using a 
spectrophotometer, which gave a similar result of the protein concentration by 
both methods. Eight hundred µl samples in 25 mM phosphate buffer at pH 7.4 
were prepared. The far UV spectra were collected at 190-260 nm with a cuvette 
using 250 µl sample in a 1 mm pathlength, at a protein concentration of 0.1-0.2 
mg/ml. Fifteen scans between 190 and 260 nm were acquired and averaged. A 
base-line scan was subtracted to produce the final average scan. The value of 
molar ellipticity ([θ] x 103 deg cm2/dmole) was plotted as a function of protein 
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concentration. The average α-helical, β-sheet, and other secondary structure 
element content in the refolded BP1-LRP6 was calculated using DICHROWEB 
server (212).  
 
3.3. Results 
3.3.1. Expression and purification of the recombinant BP1-LRP6 from 
Escherchia coli (E. coli) 
 BP1-LRP6 with N-terminus His tag was expressed in E. coli. Bacterially 
expressed BP1-LRP6 adopted random conformations and preferred forming 
oligomers by non-native disulfide bonds. In order to break the intermolecular 
disulfide bonds for monomer BP1-LRP6 protein band, all the samples in Figure 
3-4 were reduced by DTT.   
 Figure 3-4 showed the highly efficient recombinant BP1-LRP6 expression 
and the nickel chelating column purification process.  The strong protein band of 
37 kDa (BP1-LRP6) was shown in the IPTG-induced cell lysates while there was 
no induced protein expression band in the control ( lanes 1 and 2). Large 
quantities of recombinant BP1-LRP6 expressed inside E. coli caused protein 
aggregation and formed inclusion bodies. We had to use 6 M urea in the 
purification buffer and repeated the sonication step three times in order to extract 
the recombinant BP1-LRP6. The extracted recombinant BP1-LRP6 in the buffer 
was loaded onto a nickel chelating column, followed by extensive washings to 
reduce non-specific proteins from binding. BP1-LRP6 was eluted out with 1 M  
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Figure 3-4: A 12% reducing SDS-PAGE gel, showing the induced expression of 
BP1-LRP6 in E. coli and its purification by using nickel chelating column.  
 
imidazole. The elution was dialyzed and lyophilized to obtain pure protein 
powder. By using this high-yield recombinant protein expression method, we 
could routinely obtain about 70 mg of pure BP1-LRP6 protein powder from 500 
Lane 1: E. coli cell lysates after IPTG induction. Lane 2: E. coli cell lysates without 
IPTG induction as a negative control. Lane 3: the cell extract before loading onto the 
column. Lane 4-6: the cell extract from the 1st sonication, 2nd sonication, and 3rd 
sonication. Lane 7: the flow through after loading. Lane 8: the flow through of the 
binding buffer wash. Lane 9: the flow through of the washing buffer wash. Lane 10: 
the elution. 
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ml cell culture. Pure bacterially expressed BP1-LRP6 was stored at -20 °C for 
further experiments.  
  
3.3.2. Highly efficient protein delivery by QQ-reagent 
 To optimize the protein delivery condition for in vivo refolding of BP1-
LRP6, we conducted a time course of protein delivery experiment for 3 hours. 
Bacterially expressed BP1-LRP6 was modified with QQ-reagent for overnight at 
4 °C. The QQ-modified BP1-LRP6 was mixed with serum-fr ee DMEM to reach 
the final concentration of 0.1 mg/ml. Dishes containing 80% confluent HeLa cells 
were incubated with the protein delivery medium for different periods of time. 
Every half hour, one dish of HeLa cells was taken out and was suspended in the 
SDS-PAGE loading buffer. All the samples were analyzed by a 12% SDS-PAGE. 
In order to observe the monomer band of BP1-LRP6, we ran a duplicate SDS-
PAGE under reducing condition.  
 Figure 3-5 showed the gradual appearance of a monomer BP1-LRP6 
protein band (red arrow) in the Hela cell lysates samples from 0.5 hour to 3 
hours. Under a reducing condition (Figure 3-5, right panel), the intensity of the 
BP1-LRP6 protein band was significantly increased (red arrow). The data 
demonstrated that the protein delivery of BP1-LRP6 into Hela cells was linear, 
maximizing around 2 hours post delivery. 
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Figure 3-5: 12% SDS-PAGEs of a time course of the QQ-delivery of the BP1-LRP6 
into HeLa cells.  
 
 Bacterially expressed BP1-LRP6 was labeled with amine-reactive 
ArrayIt®Green540 and delivered into Hela cells with the QQ-reagent and imaged 
using confocal fluorescence imaging (Figure 3-6). Images were taken after 1 and 
2 hours after protein delivery.  After 1 hour protein delivery, the fluorescence 
images showed that most of BP1-LRP6 was located in the perinuclear location 
inside HeLa cells, possibly in the ER for refolding (Figure 3-6, top panel).This 
was confirmed by the imaging data after 2 hours of protein delievery, showing 
that more BP1-LRP6 proteins were located into the perinuclear area of the HeLa 
cells (Figure 3-6, bottom panel). This result confirmed our result of the time 
Lane CT: the Hela cell lysis after loaded with QQ-reagent for 3 hours as a negative 
control. Lane M: protein marker. Lane 1-6:  the Hela cell lysis after loaded with QQ- 
modified BP1-LRP6 for 3 hours, 2.5 hours, 2 hours, 1.5 hours, 1 hour and 0.5 hours. 
Lane 7: the bacteria expressed BP1-LRP6 powder. Lane 8: the bacteria expressed 
BP1-LRP6 powder with DTT. Left panel: Without DTT. Right panel: With DTT.  
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course of BP1-LRP6 delivery, suggesting that 2 hour protein delivery appeared to 
be the optimal protein delievery time (Figure 3-5).  The QQ-reagent is highly 
efficient for protein delivery with most of bacterially expressed BP1-LRP6 being 
delivered inside of HeLa cells, ready for refolding. 
 
Figure 3-6: Confocal fluorescence images of the Hela cells with the delivered BP1-
LRP6.  
 
BP1-LRP6 was first labeled with small molecular fluorophore (ArrayIt® Green 540 
amine-reactie dye) and then modified with QQ-reagent for protein delivery. 
Fluorescence images (on the left) and DIC images (on the right) were taken after 1-
hour and 2-hour protein delivery.  
                                                                               130 
 
 
 
 A relatively high concentration of BP1-LRP6 was kept inside HeLa cells 
during refolding. After delivering bacterially expressed BP1-LRP6 for 2 hours, we 
changed the protein delivery medium for fresh serum-free DMEM for another 
overnight incubation. We took samples of the HeLa cells and ran the cell lysates 
sample on a SDS-PAGE. We found that BP1-LRP6 accumulated inside HeLa  
 
Figure 3-7: A 12% SDS-PAGE analysis to semi-quantify the delivered BP1-LRP6 
inside HeLa cells.  
 
All the samples were reduced with DTT. Lane M: protein marker. Lane 1-3: 10 ul, 15 
ul and 20 ul of the Hela cell lysates sample after 2 hours protein delivery and an 
overnight incubation. Lane 4: the intact Hela cell lysates as negative control. Lane 5: 
the modified BP1-LRP6 before loading. Lane 6: the remaining undelievered BP1-
LRP6 in the medium after 2 hours of protein delievery. Lane 7-10: 10 ul bacterially 
expressed BP1-LRP6 powder at the concentrations of 0.25 mg/ml, 0.5 mg/ml, 0.75 
mg/ml and 1 mg/ml. The concentration of the delivered BP1-LRP6 was between 0.25 
mg/ml and 0.5 mg/ml.  
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cells (Figure 3-7). To semi-quantify the amount of BP1-LRP6 inside of HeLa 
cells, we ran the HeLa cell lysates samples and the bacterially expressed BP1- 
LRP6 samples with known concentrations under the same reducing condition 
(Figure 3-7). We found that the delivered BP1-LRP6 inside Hela cells reached 
the concentration range between 0.25 mg/ml and 0.5 mg/ml (lanes 7-10, Figure 
3-8). It was surprising that the protein delivery could be so efficient for BP1-LRP6 
as compared to that for LBD-ApoER2 (Chapter 2).  The delivered protein 
appeared stable inside HeLa cells even after overnight incubation. The 
differences in delievery efficiencies could be related to the unique biochemical 
properties of individual proteins (modified by QQ-reagent to differing extents, 
charge, etc.). 
 
3.3.3.   Inside of HeLa cells, the delivered BP1-LRP6 was under refolding 
process, showing increasing ligand-binding ability in the Far-western blot 
  MESD is an ER chaperone especially binding properly folded YWTD β-
propeller domains of LRP5/6 and escorting them throughout the secretary 
pathway (209). We used MESD as our far-Western blot probe to specifically bind 
and detect the properly folded and biologically functional BP1-LRP6 in the 
samples.  
 Bacterially expressed BP1-LRP6 was modified by QQ-reagent and was 
delivered inside of HeLa cell for 4 hours. Each hour, we collected the sample of 
HeLa cells harboring delivered BP1-LRP6. All the HeLa cell samples were lysed  
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Figure 3-8: Far-Western blot (MESD as probe) of BP1-LRP6.  
 
and, with the bacterially expressed BP1-LRP6 sample, the HeLa cell lysates 
were subjected to the far-Western blot. Our result showed that the delivered 
BP1-LRP6 gradually underwent conformational changes inside of HeLa cells, 
showing stronger and stronger binding ability to its probe, MESD, as time went 
on (as shown in Figure 3-8). This data suggested that once the bacterially 
expressed BP1-LRP6 was delivered inside of HeLa cells, the refolding process 
began. More bacterially expressed BP1-LRP6 was refolded and increasing 
amounts of properly folded BP1-LRP6 appeared, showing its specifically binding 
The HeLa cells with delivered BP1-LRP6 were collected at different time point. The 
samples were lysed and were subjected to far-western blot using MESD as probe. 
Lane1: 1 hour. Lane 2: 2 hours. Lane 3: 3 hours. Lane 4: 4 hours. Lane 5: the 
bacterial expressed BP1-LRP6 without refolding as negative control. The red arrow 
shows the band site of BP1-LRP6. (Courtesy of Dr. Qianqian Li). 
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to the ligand (our probe) MESD. At this point, we confirmed that the delivered 
BP1-LRP6 can be refolded inside of HeLa cells. Given refolding time long 
enough, more BP1-LRP6 can be properly folded showing its biological function to 
bind MESD and eventually the delivered BP1-LRP6 can be totally refolded while 
the persistent unfolded BP1-LRP6 can be degraded by the active mechanisms 
such as ERAD or UPR. 
 
3.3.4. Optimization of the protein refolding protocol for BP1-LRP6 
 Protein refolding inside Hela cells takes time. We conducted experiments 
to monitor the fate of the delivered BP1-LRP6 (Figure 3-9). Our recombinant 
BP1-LRP6 does not have a signal peptide at the N-terminus, thus the refolded 
BP1-LRP6 remains inside HeLa cells. We tried to prolong the in vivo refolding 
time by incubating the protein delivered HeLa cells with serum-free DMEM for 
three days (Figure 3-9). Every 24 hours, HeLa cell samples were taken. All the 
samples were incubated with 10 mM DTT before being analyzed by 12% SDS-
PAGE for a monomer BP1-LRP6 protein band. Our results showed that the 
amount of BP1-LRP6 inside HeLa cells was significantly decreased in the first 
day of in vivo protein refolding. However, in the subsequent two days of in vivo 
refolding, the amount of BP1-LRP6 inside HeLa cells was relatively stable, 
showing only slight decrease. After 3 days of refolding, the HeLa cells still 
appeared morphologically normal (data not shown).  Since a BP1-LRP6 protein 
band (red arrow) remained detectable and the protein refolding time was 
maximal to 3 days.  These results suggest that 2 hours of protein delievery of the  
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Figure 3-9: The time course experiment on refolding BP1-LRP6 inside HeLa cells.   
  
bacterially expressed BP1-LRP6 into Hela cells by the QQ-reagent (Figure 3-5) 
followed by 3 days of protein refolding inside of the cells (Figure 3-9) are likely 
the optimized conditions for the refolding of BP1-LRP6 inside Hela cells. 
 Mammalian cells have developed mechanisms to actively remove toxic 
proteins, such as unfolded or misfolded proteins. Not only the active ATP-
Lane M: protein marker. Lanes 1-3: the Hela cell lysates after incubation for 3 days, 2 
days and 1 day post protein delievery. Lane 4: the Hela cell lysates of negative 
control. Lane 5: the Hela cell lysis after 2 hours protein delivery. Lane 6: the modified 
BP1-LRP6 before loading. Lane 7: the remaining BP1-LRP6 in the protein delivery 
medium after 2-hour of protein delievery. All the samples were in the presence of 10 
mM DTT. 
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consuming ER associated degradation (ERAD) and unfolded protein response 
(UPR) but also the unspecific proteolytic enzymes of the lysosome can actively 
degrade the toxic unfolded or misfolded proteins inside mammalian cells 
(Chapter 1). Also, mammalian cells can secrete out the toxic proteins and 
compact them into a less toxic amyloids stocked in the extracellular tissue. 
Ultimately, accumulation of these toxic proteins in the cell cytoplasm can cause 
apoptosis. It is unlikely that the unfolded BP1-LRP6 could escape away from 
such a well-organized and strict control, being kept inside healthy HeLa cells. We 
thought that the relatively stable stock of BP1-LRP6 inside HeLa cells after 3 
days of in vivo protein folding was the potentially refolded BP1-LRP6.  
 
3.3.5. The high yield of refolded BP1-LRP6  
 Is the refolded BP1-LRP6 properly folded? How is its structure organized? 
To address these questions, we need first to purify the refolded BP1-LRP6 from 
the HeLa cells after three-day in vivo protein folding (Figure 3-10). In order to 
keep the native conformation of the refolded BP1-LRP6 as it was inside Hela 
cells, no denaturing reagent was used in the buffers of nickel chelating column 
purification. Due to the protein-protein interactions inside HeLa cells, non-specific 
proteins could be co-purified (data not shown). To solve the problem, we 
modified the purification protocol by increasing NaCl concentration up to 1 M in 
the buffers. This modification greatly improved the quality of the eluted refolded 
BP1-LRP6. The column was extensively washed and the refolded LRP6 was 
eluted by an imidazole concentration gradient (lanes 7-9, Figure 3-10).  
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 To identify the purified refolded BP1-LRP6, Western blot against anti-His 
tag antibody and anti-LRP6 were applied to the same quantity of the purified 
refolded BP1-LRP6 and the bacterially expressed one (Figure 3-11). Purified 
refolded BP1-LRP6 showed strong positive signals detected by both anti-His tag 
antibodies and anti-LRP6 antibodies, identifying the re-purified protein as the 
refolded BP1-LRP6 (Figure 3-11). In the anti-His tag Western blot, both the 
bacterially expressed and the refolded protein powders showed positive signals 
of BP1-LRP6 at the monomer position. Compared with the bacterially expressed 
BP1-LRP6, our in vivo protein refolding method had significantly enriched 
monomeric BP1-LRP6 in the sample.  
 
Figure 3-10: Re-purification of refolded BP1-LRP6 from Hela cells.   
Lane 1: the bacteria expressed BP1-LRP6 powder. Lane 2: the Hela cell extract 
before loading onto His•Bind column. Lane 3: the flow through after loading. Lane 4: 
the flow through of binding buffer washing. Lane 5-6: the flow through of washing 
buffer wash (20 mM and 70 mM imidazole washing). Lane 7-9: the elution at 100mM, 
250mM and 1M imidazole concentrations. All the samples were treated with 10 mM 
DTT before analyzed by 12% SDS-PAGE. 
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Figure 3-11: Anti-His tag (Left panel) and anti-LRP6 (right panel) western blotting 
to identify purified refolded BP1-LRP6.  
 
 The crystal structure of the homologue of BP1-LRP6, the LDL receptor BP 
domain, had been solved (PDB file # 1IJQ) (130). In this structure, we noticed 
that the six cysteine residues in EGF-like domain formed three intramolecular 
disulfide bonds. Only the properly folded BP1-LRP6 should have structure 
similarities to the LDL receptor BP domain; its cysteine residues should also only 
form intra-domain disulfide bonds. If folded properly, the oligomeric species 
The left panel: all the protein samples were at 50 ng/µl and without DTT. Lane 1: 10 
ul (500 ng) bacteria expressed BP1-LRP6. Lane 2: 10 ul (500 ng) purified refolded 
BP1-LRP6. The right panel: all the protein powder sample were at the concentration 
of 50 ng/ul. Lane 1-3: 4 ul, 8 ul, and 12 ul (200, 400, and 600 ng, respectively) 
purified refolded BP1-LRP6. Lane 4-6: 4 ul, 8 ul and 12 ul bacterial expressed BP1-
LRP6  at the same concentrations. 
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(intermolecular bonds) should be greatly reduced while the monomeric band 
(intramolecular bonded form) (37 kDa) should be greatly enriched.  This is 
exactly what was observed (lanes 1 and 2, the left panel of Figure 3-11).  This 
finding suggests that this in vivo protein refolding technique enables efficient 
refolding of BP1-LRP6. Previous published data (211) supports this conclusion, 
showing that the molecular chaperone MESD was co-overexpressed with BP1-
LRP6 to facilitate its folding. MESD dramatically enhanced the folding of BP1-
LRP6, and the properly folded BP1-LRP6 was secreted into the medium. Only 
one monomer band of the secreted BP1-LRP6 was shown in their Western blot. 
Therefore, the monomer BP1-LRP6 represents the potential properly folded BP1-
LRP6. Our purified refolded BP1-LRP6 had large percentage of the properly 
folded BP1-LRP6.  
 The in vivo protein refolding method was optimized specifically for BP1-
LRP6. The bacterially expressed BP1-LRP6 was modified by the QQ-reagent at 
0.1 mg/ml (final concentration). Protein delivery was conducted for 2 hours and 
protein was extensively refolded inside of HeLa cells for 3 days. After 3 days of  
refolding, the potentially properly refolded BP1-LRP6 was purified by HisBind 
(Nickel chelating) column chromatography. A high yield of the refolded BP1-
LRP6 was achieved through this in vivo refolding process. The yields of the 
refolded BP1-LRP6 from two independent purification schemes are shown in 
Table 3-1. We routinely obtained a yield of around 60%. 
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Table 3-1: The final yield of the purified refolded BP1-LRP6 using in vivo protein 
refolding technique.  
 
3.3.6. Well-defined secondary structure shown in the far-UV CD spectrum  
of refolded BP1-LRP6  
 Far-UV circular dichroism (CD) spectroscopy is an excellent tool for rapid 
determination of the secondary structure and folding properties of proteins. CD 
spectra of the purified refolded BP1-LRP6 and the bacterially expressed BP1-
LRP6 were recorded in 50 mM sodium phosphate buffer at pH 7.4. The results 
showed very different spectra for these two samples (Figure 3-12). While the 
spectrum of the bacterially expressed BP1-LRP6 was more characteristic of a 
random coil, the spectrum of the purified refolded BP1-LRP6 showed a positive 
CD signal at 193 nm and negative CD signal near 218 nm, suggesting a 
predominantly defined β-sheet structure. This result is consistent with the crystal 
structure of the homologue of BP1-LRP6--- the LDL receptor BP domain, in 
which six YWTD repeats together fold into a six-bladed β-propeller and each 
blade is consisted of four-stranded β-sheets. Also, in the CD spectrum of the 
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refolded BP1-LRP6, the negative CD peaks centered near 208 nm and 222 nm 
suggest that the refolded BP1-LRP6 also contains some α- helical structure.  
 To further quantify the result, we sent the CD data of the refolded BP1-
LRP6 to the DICHROWEB server (212). DICHROWEB is a user-friendly interface 
to analyze CD spectra. As the spectra of proteins that have been characterized 
by x-ray crystallography are standards, DICHROWEB compared the spectra of 
the refolded BP1-LRP6 with the standards using programs such as CONTINLL, 
VARSLC, K2d, CDSSTR, and SELCON3 (212), assuming that the spectrum of a 
     
Figure 3-12: Far-UV circular dichroism (CD) spectrum of the bacterially expressed 
BP1-LRP6 and the purified refolded BP1-LRP6.  
The right panel showed the CD samples on 12% SDS-PAGE. Lane 1 is the refolded 
BP1-LRP6 protein  sample. Lane 2 is the bacterially expressed BP1-LRP6 protein 
sample. Both samples had reacted with 10 mM DTT. 
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protein can be represented by a linear combination of the spectra of its 
secondary structural elements, plus a noise term, which includes the contribution 
of aromatic chromophores and prosthetic groups (213). The calculated 
secondary structure element content of the refolded BP1-LRP6 was shown as 
Table 3-2. Compared with its homologue---the LDL receptor BP domain, the 
refolded BP1-LRP6 had almost the same high content of β- sheet and small 
percent of α- helices. The percentage numbers of the secondary element are so 
close that it strongly supports the idea that the refolded BP1-LRP6 adopts a 
similar conformation as the LDL receptor BP domain, further confirming that our 
refolded BP1-LRP6 was properly folded and adopted a defined and a potentially 
native conformation. 
Table 3-2: Comparison of the secondary structure content of the refolded BP1-
LRP6 (using DICHROWEB web server) with that of the BP domain of LDLR (130, 
212). 
         Secondary Structure Alpha-helix (%) Beta-sheet (%) Loop (%) 
The refolded BP1-LRP6 2.6 41.0 56.4 
LDL receptor YWTD-EGF  2.0 46.0 52.0 
 
 
3.4. Discussion   
LRP5 and LRP6 are unique members of LDL receptor family. Instead of 
having clusters of ligand binding repeats in the extracellular domain to exert 
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ligand-binding function, the YWTD β-propeller/EGF (BP) modules occupies large 
part of the extracellular domain and plays an important role in ligand binding. 
Especially in Wnt signal transduction, LRP5/6 acts as co-receptor of the 
canonical Wnt/β-catenin pathway. Malfunctions of LRP5 can cause disorder in 
bone metabolism (152). LRP6 mutations associate with coronary artery disease, 
Alzheimer’s disease, and cancer (192). Structural studies on LRP5/6 are very 
important to understand the mechanisms of the above diseases.  
BP1-LRP6 is a 328 amino acids (37 kDa) fragment, including six YWTD β-
propeller motifs and one EGF-like repeat. No previous structural study on LRP6 
has been reported. But, as the homologue of BP1-LRP6, the x-ray 
crystallography structure of LDL receptor YWTD β-propeller/EGF (BP) domain 
has shown that the six YWTD repeats of LDL receptor was folded into a six-
bladed β-propeller domain. Each blade consisted of four-stranded β-sheets. 
EGF-like domain tightly packs against the second and third blades of the 
propeller. 
Refolding the bacterially expressed BP1-LRP6 in vitro is challenging. BP1-
LRP6 is a 37 kDa protein with multiple motifs. During in vitro refolding, the 
exposed hydrophobic residues in the refolding intermediates may cause 
irreversible aggregation by hydrophobic interactions or non-native hydrogen 
bonding. Also, without help of molecular chaperones and folding enzymes, 
especially RAP and MESD, it is very difficult to form native intra-repeat disulfide 
bonds in the EGF-like repeat of BP1-LRP6 for a proper folding.  
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Instead of using traditional in vitro protein refolding methods, we used our 
novel in vivo protein refolding technique to refold bacterially expressed BP1-
LRP6. With optimized conditions, QQ-reagent efficiently delivered large quantity 
of bacterially expressed BP1-LRP6 inside HeLa cells within two hours (Figure 3-5 
to 3-7). Protein refolding was extensively processed inside HeLa cells for three 
days (Figure 3-9). During these three days, the bacterially expressed BP1-LRP6 
underwent refolding facilitated by the ER molecular chaperones and folding 
enzymes. Persistent unfolded or misfolded BP1-LRP6 could be actively 
degraded by the ERAD or UPR mechanism in the ER.  
During BP1-LRP6 folding, MESD may play a key role to escort the 
properly folded BP1-LRP6 travel from the ER to Golgi. We delivered a large 
quantity of BP1-LRP6 inside Hela cells for refolding (Table 3-1). The quantity 
may be above the threshold of endogenous MESD, causing the refolded BP1-
LRP6 to be retained inside of the Hela cells. Also, the refolded BP1-LRP6 was 
lacking a signal peptide, which may cause the difference in localization 
(intracellular versus secreted) of the refolded BP1-LRP6. 
We used a nickel chelating column to purify the refolded BP1-LRP6 from 
HeLa cell lysates (Figure 3-10). We found our purified and potentially refolded 
BP1-LRP6 was greatly enriched for the monomeric form (Figure 3-11). The 
refolding efficiency and the final yield for this cysteine-rich, large-sized protein 
were so high that nearly 60% percent of the delivered BP1-LRP6 was refolded 
and re-purified. To futher purify our refolded BP1- LRP6, the protein could be 
applied to a size exclusion chromatography to separate the monomeric species 
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from the higher molecular weight oligmeric ones. A functional assay was 
performed to prove that the BP1-LRP6 obtained by our novel in vivo protein 
refolding technique was properly refolded and biologically functional (Figure 3-8).  
This provided more evidence that the refolded BP1-LRP6 was in a native 
conformation. 
The secondary structure and folding properties of the refolded BP1-LRP6 
was studied by far-UV circular dichroism (CD). Our CD data showed that the 
refolded BP1-LRP6 adopted a β-sheet rich conformation while the spectrum of 
the bacterially expressed BP1-LRP6 was more characterized as random coil 
(Figure 3-12). The DICHROWEB server further analyzed and quantitated the CD 
data (Table 3-2). The analysis showed that the refolded BP1-LRP6 and its 
homologue, the LDL receptor BP domain shared almost the same percentage of 
α-helix and β-sheet in their structure, suggesting that our refolded BP1-LRP6 
adopted similar defined conformation as its homologue, the LDL receptor BP 
domain. Our in vivo protein refolding technique is unique because it gives a more 
physiological relevant in-cell environment for protein refolding. In this 
environment, not only the refolding is assisted by molecular chaperones and 
folding enzymes in the ER, but also the folding quality is strictly monitored by a 
complex quality control system inside the mammalian cells. Compared with 
traditional in vitro protein refolding methods, our method is much more efficient in 
large protein refolding, which has been demonstrated in the refolding of LBD-
apoER2 (Chapter 2). However, endogenous ER chaperones and folding 
enzymes have their threshold for protein folding. This may cause the retention of 
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the refolded protein inside of the mammalian cells or partially refolding of the 
delivered protein. We confronted these problems when we challenged our in vivo 
protein refolding technique with cysteine-rich, large-size protein, BP1-LRP6. We 
hope we can overcome these problems by further optimizing our in vivo protein 
refolding technique or by engineering mammalian cells that can sustain large 
quantity protein refolding. 
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CHAPTER IV 
Conclusion and future directions 
4.1.  Conclusion 
Studies of in vitro protein refolding allow us to understand fundamental 
aspects of the folding mechanisms without the complications of the biological 
environment. From Anfinsen’s RNase renaturation experiment, it has been long 
accepted that all the driving forces and guiding information of protein folding are 
embedded in the primary amino acid sequence of a protein and no external 
template is required. Under physiological conditions, the native state protein 
adopts the most thermodynamically stable conformation. In vitro refolding 
process is a good model for defining the types of intramolecular interaction that 
drive polypeptide folding and understanding the mechanisms of protein folding. 
However, in vitro refolding cannot accurately reflect the folding process of 
nascent proteins inside of cells due to the differences between protein folding in 
the intracellular environment and those in the test tube: 1) the intracellular 
environment is a highly crowded macromolecular environment; 2) folding inside 
of the cell is facilitated by molecular chaperones and folding enzymes and must 
be accomplished in the context of the synthesis of polypeptide chains on 
ribosomes; 3) cells are an intrinsically dynamic system. Protein folding 
experiments in vitro may not mimic the dynamics states in vivo. Ultimately,  
protein folding must be studied in a cellular context. It is necessary to develop 
new techniques using new in vivo  systems to integrate the best aspects of both 
                                                                               147 
 
 
 
the high-level bacterial expression system and the efficient cellular folding 
machinery of mammalian cells.  
Our novel in vivo protein refolding technique uniquely integrates these two 
aspects. This technique first expresses recombinant proteins in E. coli with a very 
high-yield and then deliver the bacterially expressed pure protein directly into the 
ER of HeLa cells, using the QQ- protein delivery system, to properly refold the 
protein by the comprehensive protein folding machinery inside of mammalian 
cells. We drive the proteins into the inclusion bodies for the purpose of high yield 
and high purity. We then purify the recombinant proteins under denatured 
conditions since the bacterially expressed proteins will be refolded in the HeLa 
cells. The key step of this in vivo protein refolding technique is the QQ-protein 
delivery system that allows specific delivery of the bacterially expressed proteins 
into the ER for efficient refolding. This novel in vivo protein refolding technique 
offers a unique tool for protein folding study as well as for broader applications, 
such as therapeutical protein productions.  
This thesis also presents the applications and optimizations of our novel in 
vivo protein refolding technique on two challenging proteins: LBD-apoER2 and 
BP1-LRP6. ApoER2 is an important LDL receptor super family member involved 
in ApoE metabolism in brain and the onset of Alzheimer’s disease. The LBD-
apoER2 contains 7 ligand binding repeats. Each repeat contains 6 cysteines 
forming 3 intra-repeat disulfide bonds, plus one Ca2+-binding site. Bacterially 
expressed LBD-apoER2 formed non-native disulfide bonds, causing multiple 
conformations and aggregation. LRP6 is the co-receptor of Wnt signalling 
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pathway, involved in cell proliferation, differentiation and mobility. The homologue 
of BP1-LRP6, BP domain of LDL receptor, adopts a β-sheet rich conformation. In 
BP domain of LDL receptor, the YWTD β-propeller module is composed of six β-
strand blades and the C-terminal EGF-like module is stabilized by three intra-
domain disulfide bonds. Bacterially expressed BP1-LRP6 was misfolded and 
formed large amounts of oligomers.  
By using our in vivo protein refolding technique, we efficiently delivered 
the misfolded proteins into the ER of HeLa cells. Under the physiological 
environment of ER and with the help of molecular chaperones and folding 
enzymes, the misfolded proteins were efficiently refolded into their native 
conformations. The refolded LBD-apoER2 displayed RAP binding function, 
implying its proper conformation. The refolded BP1-LRP6 also showed biological 
function of MESD binding ability, indicating the appearance of native 
conformation after refolding. Far-UV circular dichroism spectra of the refolded 
BP1-LRP6 indicated a β-sheet rich structure. The data analysis of the far-UV 
circular dichroism spectra provided indirect evidence that the refolded BP1-LRP6 
adopted a remarkably similar secondary structure as its homologue --- BP 
domain of LDL receptor. Based on our results, we concluded that the application 
of our novel in vivo protein refolding method gave high yields of properly folded 
LBD-apoER2 and BP1-LRP6. 
This novel in vivo protein refolding technique not only provides an efficient 
tool to obtain large quantities of properly folded recombinant proteins with stable 
isotopes for structural apporaches such as NMR spectroscopy, but also opens 
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interesting new perspectives for producing biological active polypeptides and 
proteins with therapeutic value on a large-scale. Moreover, this technique bridges 
the existing technical gap between in vitro protein folding and folding in living 
cells and can be used to gain a fundamental understanding of dynamic 
intracellular folding mechanisms in the living mammalian cells by studying the 
folding of the radioactive amino acid labelled recombinant proteins inside of 
mammalian cells. Or, as the fluorescence based techniques (such as fluorescent 
resonance energy transfer, FRET) develop, we can expect to study 
conformational changes of proteins in the living cell. 
    
4.2. Future Directions 
 We have successfully refolded LBD-apoER2 and BP1-LRP6 into their 
native comformations with biologically functions by applying the in vivo protein 
refolding technique. The logical next step is to investigate the biochemical and 
structural characters of these properly folded proteins under physiologically 
relevant circumstances. One of strengthes of our in vivo protein refolding is that 
we can efficiently refold isotope-labelled bacterially expressed proteins into their 
native conformations. With isotope labelling, the refolded LBD-apoER2 and BP1-
LRP6 can be dissolved in physiologically relavent buffers, ready for NMR 
structural studies. BP domains of LRP6 is involved in Wnt signalling pathway and 
LBD-apoER2 may be involved in the onset of Alzheimer disease. They are 
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potentially important drug targets. Detailed structure information on these two 
proteins can be very helpful for drug design. 
 The folding of the cysteine-rich ligand binding repeats of LBD-apoER2 
relies on a special ER/Golgi resident molecular chaperone RAP (138). RAP 
escorts the ligand binding domain and inhibits pre-mature ligand binding through 
the secretary pathway. RAP exerts high binding affinity to the ligand binding 
domain of the LDLR family (KD~ 1-10 nM) in the ER (125, 138, 139). But under 
the acidic environment of Golgi, RAP is released fom the binding complex by 
lowering the binding affinity to ligand binding repeats. The RAP releasing 
mechanism in Golgi is still not clear. Acoording to the x-ray crystal structure of 
RAP-D3 and LDLR-LA3-4, A low-pH induced unfolding model was proposed 
(214). In this model, the histidine residues which are buried in the hydrophobic 
interior of  the RAP-D3 helical bundle are protonated under the low pH 
environment of Golgi and, in sequence, trigger unfolding of the helical bundle and 
dissociation of RAP-D3/LDLR-LA3-4 complex. However, Gettins’ group found 
that domain D1 of RAP also bound LA repeats of LRP with very high affinity 
(215). In their low-pH induced YWTD displacing model, the flanking YWTD 
“propeller” domains competitively bind to RAP at the two binding sites in RAP-D1 
and RAP-D3 under the low pH environment of Golgi. Thus, RAP is displaced by 
YWTD domains, releasing from LA repeats. The debating of these two models 
diverges at different study objects. The low-pH induced YWTD displacing model 
claimed for the acuteness by applying the intact RAP and three ligand binding 
repeats of LRP instead of RAP-D3 and two ligand binding repeats only of LDLR. 
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To clear the debating, we can conduct isothermal titration calorimetry (ITC) 
experiments on the protein-protein interactions between the intact RAP (available 
in our lab) and our refolded LBD-apoER2 which contains the whole ligand 
binding domain (seven ligand binding repeats) at different pH environments. This 
research will offer direct evidences to elucidate the RAP releasing mechnism in 
Golgi. 
 Protein chaperones are involved in the protein folding process inside of 
cells. For example, Bip, the abundant general ER chaperone, usually is the first 
chaperone binding to the nascent peptide chain to facilitate translocation of the 
nascent peptide chain into the ER lumen. PDI is one of the most important ER 
chaperones facilitating the native disulfide bond formation (28). RAP is the 
specific folding chaperone for the ligand-binding domain of LDLR superfamily 
members (125). MESD is the private chaperone for LRP5/6 BP domain folding 
(139). In our research, the folding threshold of endogenuous molecular 
chaperones and folding enzymes was the main factor that limits the in vivo 
protein refolding efficiency. Our QQ- protein delivery system is powerful. We can 
co-deliver important molecular chaperones or folding enzymes inside of cells with 
the proteins of interest to overcome the folding threshold problem and to further 
increase the refolding efficiency of the in vivo protein refolding technique. 
 On the other hand, the host mammalian cells could also be engineered for 
the purpose of improving in vivo protein refolding efficiency. Reports have 
provided examples of how the growth, survival, and productivity of the host cell 
can be improved through use of these genetic engineering techniques. Proto-
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oncogenes, cell cycle control genes (cyclins), growth factor genes (e.g., insulin-
like growth factor), and anti-apoptotic genes have been inserted into cell lines for 
the generation of superior recombinant protein production hosts (216). 
Improvements of in vivo protein refolding and post-translational modification can 
also be achieved by genetic engineering method. Stable cell lines can be 
generated by integrating key genes of molecular chaperones or folding enzymes 
into the host cell genome. These engineered host cell lines stably overexpress 
these important molecular chaperones or folding enzymes and they can be used 
as the refolding host cell lines to enhance the refolding ability. Thus, the protein 
refolding efficiency by using these engineered host cells may be significantly 
improved. 
 The establishment of a basis for understanding the determinants of protein 
folding has the potential to transform our understanding of many of the most 
perplexing issues surrounding protein folding diseases, and perhaps most 
importantly, the true nature of misfolded pathogenic protein species. Our in vivo 
protein refolding technique has opened the field for in vivo analysis of protein 
folding diseases, which has previously only been possible in vitro. We believe 
this approach may become a fundamentally important technique that could aid in 
understanding the protein folding and the complex chaperone networks inside of 
cells and its physiological relevance could, ultimately, be of clinical benefit.  
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Figure 3-3: Ribbon representation of the YWTD domain and adjacent C-terminal 
EGF-like module (E3) of the LDL receptor, colored to point out the six YWTD 
repeats of the six-bladed propeller. Adapted from Jeon,H., Meng, W., Takagi, J., Eck, 
M.J., Springer, T.A., and Blacklow, S.C. (2001) Implications for familial 
hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. 
Nat Struct Biol  8, 499-504. 
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Proteins perform their functions in their native folded states and misfolding 
of proteins may cause severe diseases, including Alzheimer’s disease, 
Parkinson’s disease, prion disease and diabetes. Understanding protein folding 
is important for us to engineer proteins to treat these diseases. For protein 
therapeutics, large quantities of properly folded and functional proteins are 
required. The current technology produces recombinant proteins using either 
eukaryotic or prokaryotic expression system, both of them have major problems 
that prevent production of large quantities of properly folded and functional 
human proteins for protein therapeutics. 
Although the eukaryotic cells have comprehensive folding machinery that 
contains chaperones and folding enzymes and a complex quality control (QC) 
system to ensure that only properly folded proteins will be generated to perform 
their functions, either intracellular or extracellular, the protein yield is usually very 
                                                                               203 
 
 
 
low. Protein production using this system is usually costly. In contrast, 
prokaryotic cells can be used to produce large quantities of recombinant human 
proteins at a low cost. However, the produced human proteins using prokaryotic 
cells usually misfold and are not functional due to the much simpler protein 
folding machinery and QC system of these prokaryotic cells. To solve this 
problem, the in vitro protein refolding technique has been developed that either 
mimics the intracellular redox conditions to promote protein folding at a diluted 
concentration or uses column chromatography to refold the misfolded 
recombinant proteins. Although this in vitro protein folding technique has some 
success for small proteins with simple folds, the refolding efficiency is generally 
very low. For large proteins of complex folds of multiple domains, this in vitro 
protein refolding technique is usually not working. 
To solve these challenges, our lab recently developed an in vivo protein 
refolding technique that uses the intracellular folding machinery and QC system 
of the Endoplasmic reticulum (ER) of mammalian cells to refold the misfolded 
recombinant proteins produced using bacterial expression system. This novel 
technique uses the QQ-protein delivery technology developed in our lab to 
directly deliver bacterially expressed proteins into the ER for refolding. We 
showed that the intracellular folding machinery of mammalian cells had a large 
capacity to properly refold large quantities of misfolded bacterially expressed 
proteins and the QC system of the mammalian cells ensured that only properly 
folded proteins followed the normal intracellular trafficking pathway as their 
endogenous counterparts. Since the refolded proteins contain an affinity tag, we 
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can purify the properly refolded proteins. This in vivo refolded technique takes 
the advantage of the high yield prokaryotic expression system and the 
comprehensive protein folding machinery/QC system of mammalian cells to 
efficiently produce large quantities of properly folded and biologically functional 
proteins. 
I optimized this in vivo protein refolding technique for the beta-
propeller/EGF domain I of LDL receptor-related protein 6 (BP1-LRP6) and the 
ligand-binding domain of apolipoprotein E receptor 2 (LBD-ApoER2). These two 
proteins contain a large number of cysteines that form intracellular disulfide 
bonds. The folding of these two proteins is very challenging. I performed 
optimizations of experimental conditions that allow me to produce large quantities 
of properly folded and functional BP1-LRP6 and LBD-apoER2. The yield of 
refolding is about 20-60%, depending on different proteins, allowing me to 
produce milligram quantity of properly refolded and functional BP1-LRP6 and 
LBD-apoER2. The Far-UV Circular Dichroism (CD) Spectrum of refolded BP1-
LRP6 showed a high percentage of beta-sheet which is consistent with the x-ray 
crystal structure of the beta-propeller/EGF domain of low-density lipoprotein 
receptor (LDLR). Refolded LBD-apoER2 showed the biological function of active 
binding the chaperone receptor-associated protein (RAP) in the ligand-blotting 
assay. My results suggested that, as a new tool, this protein refolding technique 
can be used to produce large quantities of properly folded and biologically 
functional proteins for many applications including protein therapeutics to treat 
human disease, structural biology and protein folding studies. 
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